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Abstract
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Autoimmune diseases occur in up to 3-5% of the general population and represent a diverse
collection of diseases with regards to clinical manifestations. The unifying factor of autoimmune
diseases is tissue and organ damage as a result of an immune response mounted against self-
antigens.
Systemic lupus erythematosus (SLE) is considered a prototype of human systemic
autoimmune diseases. The etiology of SLE is as yet largely unknown, but both epidemiological
and genetic data suggest an interplay between numerous and varying genetic and environmental
factors.
There is compelling evidence for a strong genetic component in SLE. The disease has a high
λsibs value and familial clustering is apparent. Multiple susceptibility loci have been identified,
some of which are syntenic between humans and mice and some of which overlap with other
autoimmune diseases.
This thesis is based on analysis of Icelandic multicase SLE families and Swedish SLE
patients.
Paper I is a study of the association of C4A protein deficiency (C4AQ0) with SLE in the
multicase families and shows a significantly increased frequency of C4AQ0 in the families. The
genetic basis for C4AQ0 varies and C4AQ0 is found on different MHC haplotypes, pointing to
C4AQ0 as an independent risk factor for SLE.
Paper II describes the association of low MBL serum levels with SLE in the families and
identifies low MBL as risk factor for SLE in families that carry the defect. Low MBL was
furthermore found to mediate an additive risk when found in combination with C4AQ0.
In paper III cellular expression the PD-1 co-inhibitory receptor on T cells was studied.
A polymorphism in the PDCD1 gene, PD-1.3A was previously associated with SLE in the
multicase families. The polymorphism is thought to disrupt expression of the gene and may lead
to decreased expression of the PD-1 receptor. The study demonstrates lower PD-1 expression
in SLE patients and relatives in correlation to the PD-1.3A genotype.
Paper IV is a compiled analysis of the SLE families, including PD-1.3A, C4AQ0, low MBL,
autoimmune diseases and autoantibody profiles. The study demonstrates clustering of different
autoimmune diseases and autoantibodies in families that are heterogenic with regards to the
genetic susceptibility factors, PD-1.3A, C4AQ0 and low MBL.
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AS Ankylosing spondylitis 
ACR American College of Rheumatology 
ANA Anti-nuclear antibodies 
APC Antigen presenting cell 
BANK B-cell scaffold protein with ankyrin repeats  
BCR B cell receptor 
BLK B lymphoid tyrosine kinase 
C1-INH C1 inhibitor  
C2Q0 C2 protein deficiency 
C4AQ0 C4A protein deficiency 
C4BP C4 binding protein  
C4BQ0 C4B protein deficiency 
CR1 Complement receptor 1 
CR2 Complement receptor 2 
CR3 Complement receptor 3 
CR4 Complement receptor 4 
CRD Carbohydrate recognition domain  
CTLA4 Cytotoxic T lymphocyte-associated antigen 4 
DAF Decay Accelerating Factor  
DC Dendritic cell 
dsDNA Double stranded DNA 
EBV Epstein Barr virus 
FcγR Fc gamma receptor 
HLA Human leukocyte antigen 
IC Immune complex  
IFN Interferon 
IL Interleukin 
IRF5 Interferon regulating factor 5 
ITGAM Integrin Alpha M 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
ITSM Immunoreceptor tyrosine-based switch motif  
LR-PCR Long range PCR  
Lyp Lymphoid tyrosine phosphatase  
MAC Membrane-attack complex  
MBL Mannan-binding lectin  
MCP Membrane bound cofactor protein  
MFI Mean of fluorescence intensity  
 
MHC Major histocompatibility complex 
MS Multiple sclerosis 
PBC Primary biliary cirrhosis 
PBMC Peripheral blood mononuclear cell  
PCR-SSP PCR with sequence specific primers 
PD-1, PDCD1  Programmed cell death 1 
RA Rheumatoid arthritis 
RT-PCR Real time polymerase chain reaction  
RUNX1 Runt-related transcription factor  
SLE Systemic lupus erythematosus 
SMA Smooth muscle antibody 
SSc Systemic sclerosis  
STAT4 Signal Transducer and activator of transcription  
TCR T cell receptor  
TG Thyroglobulin 
TNF Tumour necrosis factor  
TPO Thyroid peroxidase  
T-regs T regulatory cells 




The role of the immune system is to guard the host against foreign 
organisms. Central to the development of a “healthy” immune response is 
self-tolerance or the ability of the immune system to discriminate between 
self-antigens (components of the body, such as nucleic acids and proteins) 
and foreign antigens. Useful cells that recognize foreign antigens are 
retained and recruited to mount an immune response while dangerous cells 
responsive to self-antigens are destroyed or inactivated.  
The complexity and potential destructive power of the human immune 
system requires meticulous mechanisms of regulation to prevent the immune 
response from turning against the self.  
When the immune system mounts a hyperactive immune response against 
the host’s own healthy cells and tissues, consequences can be severe. Such 
an autoimmune attack against ‘self’ normal antigens, resulting in 
inflammation and tissue damage, can lead to one of many forms of 
autoimmune diseases.  
Autoimmune diseases 
Autoimmune diseases occur in up to 3-5% (1, 2) of the general population and 
represent a diverse collection of diseases with regards to clinical 
manifestations. The unifying factor of autoimmune diseases is damage to tissue 
and organs as a result of an immune response mounted against self-antigens. 
There is an autoimmune disease specific for nearly every organ in the 
body and autoimmune diseases vary widely with regards to the tissues 
targeted and the clinical symptoms portrayed. Autoimmune diseases can be 
classified as organ-specific or systemic autoimmune diseases (3) (Table 1). 
In organ-specific autoimmune diseases, the immune response is directed 
against a single cell type. For example, against pancreatic β-cells resulting in 
type 1 diabetes. In systemic autoimmune diseases, the immune response is 
directed against antigens that are present in almost every cell of the body, 
thus targeting a broad range of cell types and tissues. Systemic lupus 
erythematosus (SLE) is an example of a systemic autoimmune disease.  
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Table 1. Examples of systemic and organ specific autoimmune diseases. 
 
Systemic autoimmune diseases  Organ specific autoimmune diseases 
 
     
 Systemic lupus erythematosus  Vitiligo  
 Rheumatoid arthritis  Type 1 diabetes  
 Polymyositis/dermatomyositis  Graves´ disease  
 Sjögren´s syndrome  Celiac disease  
 Scleroderma  Thyroiditis   
   Hashimoto´s disease  
   Multiple sclerosis  
   Pemphigus  
   Hepatitis  
   Myasthenia gravis  
   Primary billiary cirrhosis  
     
Etiology of autoimmune diseases 
The etiology of autoimmune diseases is largely unknown, but is thought to 
be dependent on interplay between genetic and environmental factors 
(Figure 1). 
 
Figure 1. Pathways of autoimmune disease. (Adapted from Marrack 2001 (3)). 
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The genetic component in autoimmune diseases 
The effects of a strong genetic component in autoimmune diseases is 
reflected in families multicase for specific autoimmune diseases, such as 
families multicase for systemic lupus erythematosus (SLE) (4-6) and 
rheumatoid arthritis (RA) (7-9) as well as in familial clustering of different 
autoimmune diseases (10-14).  
A number of genes, both genes of the MHC and non-MHC are proposed to 
contribute to the predisposition of autoimmune disease. Current hypotheses 
concerning the pathogenesis of autoimmunity in general, have led to the 
inclusion of hundreds of genes as potential candidates and virtually any 
molecule involved in immune recognition, cell interaction, intracellular 
signalling, cytokine pathways or programmed cell death can be reasonably 
proposed (15, 16). These genes may act at different levels in diverse ways. 
Some genes influence the immune response or shape the immune repertoire, 
some genes play a role in regulating the immune response and some genes 
function at the level of the target organ affecting vulnerability. The clinical 
picture of autoimmune disease is the sum effect or interaction of a number of 
diverse genes (17). 
Genetic studies have identified chromosomal regions and genes 
associated with different autoimmune diseases and several of the 
susceptibility loci originally identified in association or linkage with a 
particular autoimmune disease have been found to overlap in different 
autoimmune diseases (18, 19).  
Environmental factors in autoimmune diseases 
Although the nature of environmental factors in triggering autoimmune 
disease is not well understood, several potential factors have been associated 
with different autoimmune diseases, including infections, UV-radiation and 
smoking. 
Infections have been implicated as potential triggers of autoimmunity (20, 
21), either through molecular mimicry of antibodies against foreign antigens 
with self components (22, 23) or indirectly by influencing cytokine 
production. Infectious microorganisms including Epstein-Barr virus (EBV) 
have been suggested as plausible candidates for playing a role in the 
pathophysiology of SLE, RA and primary Sjögren´s syndrome (24). 
Smoking has been linked to the development of SLE (25) and RA (26, 
27). Tobacco smoke has been shown to interact with genetic factors to create 
a significant combined risk of disease. Smoking is known to modulate the 
immune response and may induce an inflammatory response, immune 
suppression, alter cytokine profiles, induce apoptosis, and damage DNA 
resulting in the formation of anti-DNA antibodies (28). 
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Systemic Lupus Erythematosus (SLE) 
SLE is considered a prototype of human systemic autoimmune diseases 
because of the generalized autoimmune characteristics displayed (29). The 
clinical spectrum of SLE can vary from a mild disease affecting skin and 
joints to a severe life-threatening disease affecting internal organs. 
SLE predominantly affects women and the prevalence varies considerably 
between ethnic groups and countries (30). 
The diagnosis of SLE is based on the presence of clinical symptoms and 
autoantibodies. Due to the heterogeneity of the disease, The American 
College of Rheumatology (ACR) has established 11 criteria for classification 
of SLE (31). Table 2 lists the 1982 ACR criteria for SLE, which was used in 
this thesis. These criteria have since been revised and are still under study for 
further revision. The 1997 revised criteria, for instance, include anti-
phospholipid antibodies, while LE cell preparations have been excluded (32). 
Table 1. The 1982 American College of Rheumatology criteria for the 
classification of SLE (31).  
  Criterion 
 1. Malar rash 
 2. Discoid rash 
 3. Phosensitivity 
 4. Oral ulcers 
 5. Arthritis 
 6. Serositis 
 7. Renal disorders 
   a. Persistent proteinuria  
   b. Cellular casts of any type 
 8. Neurological disorder 
   a. Seizures (in the absence of other causes) 
   b. Psychosis (in the absence of other causes) 
 9. Hematological disorder 
   a. Hemolytic anemia 
   b. Leukopenia 
   c. Lymphopenia 
   d. Thrombocytopenia 
 10. Immunological disorder 
   a. Positive LE-cell preparation 
   b. Anti-dsDNA 
   c. Anti-Sm 
   d. False positive serological test for syphilis 
 11. Anti-nuclear antibodies (ANA) 
A person shall be said to have SLE if 4 or more of the 11 criteria are present. 
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Immunopathology of SLE 
The pathophysiology of SLE involves an autoimmune response mediated by 
autoreactive lymphocytes. Abnormalities in virtually all immune cell 
lineages have been reported in SLE including aberrant T and B cell 
interaction, T and B cell hyperactivity, abnormalities of the complement 
system, decreased phagocytic activity, increased death of cells through 
apoptosis and aberrant production of cytokines (29). 
Autoantibodies 
The presence of autoantibodies against cellular constituents is the hallmark 
of SLE. These autoantibodies are mainly directed against various nuclear 
components, such as double-stranded DNA (dsDNA) and histones, but also 
against cytoplasmic and cell membrane molecules. Antinuclear antibodies 
(ANA) are most characteristic for SLE and are present in over 95% of SLE 
patients (33). 
B cells 
SLE is associated with loss of B-cell tolerance, B-cell hyper-reactivity and 
autoantibody production. However, it remains controversial whether loss of 
B cell tolerance is primary and precedes other immune abnormalities or 
secondary to aberrant regulation by T cells and/or dendritic cells (DCs). 
Abnormalities of peripheral B cell homeostasis in SLE patients have been 
reported. Absolute numbers of B cells and memory B cells are reduced in 
SLE, but plasmablasts are expanded (34, 35). 
The mechanisms underlying aberrant B cell function in SLE are still 
largely unknown, but there are studies reporting aberrant expression of 
receptors that regulate B cell activation and signaling pathway molecules 
controlling B cell proliferation and differentiation and abnormal apoptosis 
(36, 37). All may lead to increased autoantibody production. 
Theoretically B cells may contribute to the immune dysregulation in SLE 
as antibody producing cells or as antigen presenting cells (APCs) by taking 
up and presenting autoantigens to T cells (34, 38). 
T cells 
Loss of self-tolerance also pertains to T cells. Autoreactive T cells in SLE 
characteristically exhibit a CD4+ T cell receptor (TCR) αβ	 phenotype and 
are able to provide T cell help to antibody producing B cells, produce 
interferon-γ (IFN-γ ) and moderate levels of IL-2 (39, 40). 
Functional abnormalities that have been identified in T cells from SLE 
patients include increased intracellular calcium responses and increased 
intracellular phosphorylation, recruitment of Syk tyrosine kinase to the TCR 
complex, over expression of CD40L and decreased activation-induced cell 
death (40).  
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Data on the role of CD4+CD25+ T-regulatory cells (T-regs) in SLE is 
somewhat conflicting. Decreased numbers of peripheral blood T-regs have 
been reported by most studies on SLE patients with active disease, but non-
impaired or even increased numbers of T-regs have also been described. In 
addition, both deficient and normal suppressive capacity of isolated T-regs 
has been observed in SLE patients (41). 
Monocytes and dendritic cells 
Increased apoptosis and dysregulated processing of apoptotic cells is seen in 
SLE. It has long been known that Fc and complement mediated phagocytosis 
is impaired in SLE patients. A loss in phagocytic ability has been correlated 
with complement deficiency (42). 
Increased apoptosis has been suggested as a potential source of 
autoantigens for presentation by DCs to autoreactive T cells in SLE (43, 44). 
Monocytes from SLE patients have been shown to stimulate proliferation 
of autologous CD4+ T cells in culture, thus displaying a functional 
phenotype typical of DCs. Furthermore addition of SLE serum to monocytes 
from controls has been shown to enable them to develop DC-function and 
phenotype with up-regulated expression of CD80 and CD86 and, in the 
presence of IFN-α, the ability to present antigen from apoptotic cells to 
autologous T cells (45). 
Cytokines 
Cytokines may be generally classified as Th1 or Th2 according to their 
cellular source and effector functions. In general, Th1 cytokines are pro-
inflammatory and enhance cytokine responses and Th2 cytokines are anti-
inflammatory and mediate antibody production (46). 
A balance in cytokine production is necessary for immune homeostasis 
and both diminished and excessive production of cytokines can shift the 
balance. In general, overproduction of Th2 cytokines promotes B cell 
hyperactivity and humoral responses, while overproduction of Th1 and Th17 
cytokines mediates T cell hyperactivity and inflammation (47). 
Th1 cytokines include IFN-
 and TGF-. IFN-
 increases production of 
IL-12 by DCs via a positive feedback loop and IL-12 stimulates production 
of IFN-
, thereby promoting a Th1 cytokine profile. IFN-
 furthermore 
inhibits production of Th2 cytokines, such as IL-4. 
Th2 cytokines include IL-4, IL-10 and IL-13. IL-4 acts on T helper cells 
to promote production of Th2 cytokines, including itself. IL-10 inhibits 
production of various cytokines, including T helper cell production of IFN-
 
and IL-12 production in DCs and macrophages, thus promoting a Th2 
cytokine profile. 
There are limitations to the Th1/Th2 model. Th17 helper cells are 
considered distinct from Th1 and Th2 cells. It remains unclear which 
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cytokines exactly contribute to Th17 formation, but TGF-, IL-6, IL-21 and 
IL-23 have been implicated (46). 
Several cytokines belonging to more than one Th type have been 
implicated in SLE pathogenesis. In SLE there is tendency toward a Th2 
cytokine response over a Th1 response. 
Decreased levels of IL-2 are reported in SLE patients. IL-2 is a central 
cytokine required for the activation of T, B, and NK cells. Absence of a 
regulatory cytokine, such as IL-2 may prevent effective activation and 
functioning of T cells and may also induce activation-induced cell death in T 
cells (48, 49). 
IL-10 has dual effects. It down-regulates the expression of Th1 cytokines, 
but also enhances B cell survival, proliferation, and antibody production 
(50). In SLE patients, high serum levels of IL-10 are reported that may 
promote antibody production of B cells and increased apoptosis (51-53). B 
cells from SLE patients have been shown to spontaneously produce IL-6, 
which drives proliferation and differentiation of B cells.  
Significantly elevated IL-12, IL-17 and IL-23 levels and increased 
numbers of Th17 cells has been shown in SLE patients (54). Increased IL-12 
levels promote IFN-γ production leading to polarization of peripheral cells 
toward a Th1 phenotype (55). 
Serum levels of INF-α are elevated in SLE and genes regulated by 
interferon are upregulated in SLE patients (interferon signature) (56, 57). 
The ongoing IFN- production in SLE can promote autoimmunity by 
stimulating key cells in the immune system, including lymphocytes and 
antigen-presenting DCs (58). 
Etiology of SLE 
It is widely acknowledged that the etiology of SLE combines genetic and 
environmental factors in ways still largely unknown.  
The genetic component in SLE 
Compiling evidence demonstrates the importance of genetic factors in SLE. 
Genetic predisposition in SLE is reflected in differences in the concordance 
rate for SLE in monozygotic vs. dizygotic twins. The concordance rate for 
SLE is estimated 24% - 69% for monozygotic twins, compared to 2% - 9% 
concordance for dizygotic twins (59, 60). The lack of complete concordance 
for SLE among monozygotic twins, however, highlights the importance of 
non-genetic factors. An important role for genes is furthermore supported by 
familial clustering of SLE with 10% - 12% of SLE patients having an 
affected first-degree relative (61).  
The overall genetic contribution to SLE susceptibility is also reflected in 
the comparatively high λs (ratio of the risk to siblings of an affected 
individual divided by the background population prevalence of the disease 
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where “s” refers to sibling). For SLE the estimated λs is 10-20 and as high as 
30 (4, 12, 14, 61) For comparison, estimated λs is 20for multiple sclerosis 
(MS), 15 for type 1 diabetes and 8 for RA (61, 62). 
The genetics of SLE are complex and multiple susceptibility loci have 
been identified, some of which are syntenic between humans and mice (29) 
and some of which overlap with other autoimmune diseases (16, 18). 
Through genome wide linkage and association studies (63-76) several 
genes have been associated with SLE. As may be expected there is a degree 
of ethnic heterogeneity. Some of the results have been replicated in different 
populations, but none have been replicated in all studies. The importance of 
studying genetically homogenous populations has been emphasized (5, 77-
79).  
The MHC region - HLA alleles and complement 
Like in most human autoimmune diseases, genes within the MHC region 
exhibit strong association with SLE; the HLA class I and II genes that 
encode membrane glycoproteins that present peptides for recognition by T 
lymphocytes and genes within the HLA class III region, particularly 
complement components C4 and C2 (80). 
Papers I and II describe the association of partial deficiency of C4 or 
deficiency of C4A (C4AQ0) with SLE. 
PDCD1 
Fine mapping of the 2q37 SLEB2 locus in Icelandic, Swedish, Norwegian 
and Mexican SLE patients led to identification of the PD-1.3A           
polymorphism in the PDCD1 gene (81). 
PDCD1 encodes the co-inhibitory immunoreceptor PD-1 (programmed 
death 1), which is expressed on activated T and B cells. PD-1 and its ligands,               
PD-L1 and PD-L2, on antigen presenting cells (APCs) deliver inhibitory 
signals that regulate T cell activation. PD-1.3A is suggested to affect 
transcription of the PDCD1 gene leading to decreased expression of the         
PD-1 receptor and inappropriate activation of autoreactive T and B cells 
(82). 
PD-1.3A has been associated with SLE in different cohorts as well as 
with other autoimmune diseases (81, 83-93). 
CTLA4 
The CTLA4 (cytotoxic T lymphocyte-associated antigen 4) gene maps to 
chromosome 2q33 and encodes for the CTLA4 co-inhibitory receptor. 
CTLA4 is expressed on activated CD4+ and CD8+ T cells and binds to the 
same ligands as the T cell co-stimulatory receptor CD28. CTLA4 
downregulates T cell activation and function and polymorphisms in the 
CTLA4 gene have been associated with SLE (94) and other autoimmune 
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diseases (95-101). Aberrant function of CTLA4 may lead to inappropriate 
activation of autoreactive T cells. 
FcγR 
Functional polymorphisms in the genes for FcγR 2A and FcγR 3A (Fc 
receptor for IgG) have been associated with risk for SLE by several groups 
(102-111). FcR are expressed on phagocytes and mediate clearance of 
apoptotic cells, immune complexes and pathogens and defective function of 
FcγR has been implicated in the pathogenesis of SLE (109, 112-114). 
IRF5 
Polymorphisms in the gene encoding the IRF5 (interferon regulating factor 
5) transcription factor have been associated with SLE (115, 116). 
Association of the gene encoding IRF5 was first identified in an association 
screen of genes related to type I interferon in SLE cohorts, among them 
Icelandic multicase SLE families (117). An independent study found strong 
association with a haplotype containing SNPs affecting expression levels. 
High expression of type I interferon and type I-inducible genes is commonly 
observed SLE patients (57). 
The IRF5 gene has been associated with RA (118-122), inflammatory 
bowel disease (123) and MS (124). 
STAT4 
The signal transducer and activator of transcription 4 (STAT4) is a 
cytoplasmic transcription factor involved in cytokine signal transduction. 
STAT4 transduces IL-12, IL-23, and type 1 interferon cytokine signals in T 
cells and monocytes, leading to Th1 and Th17 differentiation, monocyte 
activation, and IFN-γ production (125). 
Different polymorphisms in the STAT4 gene have been associated with 
SLE (126-128) and additive effects with IRF5 have been suggested (129, 
130). Association has also been reported with other autoimmune diseases, 
such as RA (127, 131-135), Sjögren´s syndrome (136, 137) and type 1 
diabetes (138). 
BANK1 
The B-cell scaffold protein with ankyrin repeats (BANK1) is a substrate of 
tyrosine kinases and is phosphorylated upon B-cell antigen receptor (BCR) 
stimulation. BANK1 regulates BCR-induced calcium mobilization by 
promoting tyrosine phosphorylation of IP3Receptor leading to calcium 
mobilization and B cell activation (139). 
A functional variant of the BANK1 gene was recently associated with 




A SNP in lymphoid tyrosine phosphatase (Lyp), encoded by the PTPN22 
(protein tyrosine phosphatase non-receptor 22) gene (R620WC/T), has been 
associated with SLE (75, 141-148). PTPN22 polymorphisms have also been 
associated with other autoimmune diseases, including type 1 diabetes (149-
158), RA (147, 159) and Graves' disease (160-163). A meta-analysis 
demonstrated that the PTPN22 1858T allele confers susceptibility to RA, 
SLE, Graves´ disease, type 1 diabetes and juvenile arthritis, supporting 
evidence of association of the PTPN22 gene with autoimmune diseases 
(146). Lyp, is a powerful inhibitor of T cell activation. 
BLK 
Association of SLE with the BLK gene (B lymphoid tyrosine kinase) has 
recently been reported (75, 76). A risk allele localized between BLK and the 
C8orf13 (unknown function) was associated with reduced expression of 
BLK, and increased expression of C8orf13 (76) and both genes may be risk 
factors. BLK is a B-cell specific member of the Scr family of tyrosine 
kinases and may influence proliferation and differentiation of B cells (164). 
ITGAM 
The ITGAM (Integrin Alpha M, CD11b) gene has been associated with SLE 
(75, 76, 165, 166). ITGAM encodes a subunit of complement receptor 3 
(CR3) on macrophages, dendritic cells and neutrophils. CR3 mediates 
phagocytosis of pathogens opsonized with complement iC3b, and mediates 
leukocyte adhesion and emigration from the bloodstream via ICAM-1 and 
ICAM-2 adhesion molecules (167). 
MBL2 
The MBL2 gene on chromosome 10 encodes for mannan-binding lectin 
(MBL), a component of the complement system, which mediates clearance 
of pathogens and apoptotic cells. Variant MBL2 gene alleles are associated 
with low serum MBL levels are associated with increased infections (168) 
and have been associated with SLE (169-174) and other autoimmune 
diseases (172, 175-177).  
Paper II describes the association of low MBL with SLE in Icelandic 
multicase SLE families. 
IL-10 
Promoter polymorphisms in the IL-10 gene on chromosome 1q31-32 have 
been associated with SLE (178-187) and increased serum levels of IL-10 
have been reported in SLE (51-53, 182, 188, 189). High IL-10 levels have 
been correlated with increased apoptosis in SLE and a synergistic effect 
reported in combination with apoptosis related polymorphisms (179, 190).  
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Environmental and hormonal factors in SLE 
Environmental factors and hormones are considered important in the 
etiology of SLE. Various environmental hazards have been proposed to be 
important in triggering disease or possibly also in triggering the effect of 
genes that otherwise would be kept silent. 
Environmental exposures include infectious agents, chemicals or other 
compounds capable of modulating immune responses such as 
occupational/environmental pollutants or drugs, and behavioural factors such 
as smoking and diet (191). 
Hormonal factors 
SLE predominantly affects females, particularly in their reproductive years, 
and the female to male ratio is approximately 9:1 (192, 193). Disease 
activity is sometimes modified by menstrual cycle and pregnancy, 
suggesting hormonal effects. Estrogens have been implicated in increased 
disease activity and have been shown to repress tolerance (194, 195). In men 
with SLE, low testosterone and high estrogen levels have been detected 
(196) and men with Klinefelter´s syndrome (XXY) are more prone to SLE 
(197). 
Infections 
Viruses and bacteria have been suggested as having a role in SLE. Among 
them, Epstein Barr virus (EBV) infection has been hypothesized to cause 
loss of self-tolerance via molecular mimicry of EBV-specific antibodies with 
SLE autoantigens (198). Exposure to viruses also increases antibody titers, 
which may be the result of polyclonal B cell activation. 
Drugs, occupational and life-style hazards 
UV-radiation appears to be a risk factor and trigger onset of SLE and 
photosensitivity is one of the clinical manifestation of SLE (191). Several 
drugs have been associated with drug-induced lupus, such as procainamide 
and hydralazine, which are aromatic amines or hydrazines. These drug are 
metabolized through an acetylation pathway and patients who are genetically 
slow acetylators are more prone, suggesting that the free amine or hydrazine 
moiety is a trigger (199, 200). 
Occupational risk factors have been reported in SLE, such as exposure to 
crystalline silica, solvents and pesticides. Silica exposure has been shown to 
increase the generation of apoptotic material (201, 202).  
Other potential risk factors are life-style factors such as cigarette 
smoking, lipstick and hair-dye. Cigarette smoke contains hundreds of 
potentially toxic components, including tars, nicotine, carbon monoxide and 
polycyclic aromatic hydrocarbons. Whether cigarette smoking increases the 
risk of developing SLE remains controversial and both significantly 
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increased odds ratios for SLE in smokers and unclear associations have been 
reported (25). Lipstick use has been hypothesized to be a risk factor for 
developing SLE and a recent study found a trend of greater risk for SLE with 
increased frequency of use and with a younger age of beginning lipstick use. 
Biologic effects of chemicals found in lipsticks absorbed across the buccal 
mucosa could explain this association (203). 
The major histocompatibility complex (MHC) 
The classical MHC region spans ~4 Mb on the short arm of chromosome 6 
and is the most gene-dense region of the human genome comprising over 
160 protein-coding genes and is, moreover, highly polymorphic with 
multiple allelic variants at each locus (204, 205). The MHC region is divided 
into three classes, class I, II and III (Figure 2). 
It is estimated that about 40% of the expressed genes within the MHC 
have immune system function and the MHC has been associated with 
various inflammatory and autoimmune conditions (205). 
Genes within the MHC are in strong linkage disequilibrium and are 
inherited “en bloc” as MHC haplotypes, making it difficult to determine 
which gene or allele is the real susceptibility gene and which are innocent 
bystanders. The high level of allelic variation further complicates dissection 
of disease alleles. 
 
Figure 2. Gene organization of the human MHC on chromosome 6. 
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MHC class I, II and III genes 
MHC class I genes 
Within the MHC class I region lie genes that encode for HLA-A, B and C 
molecules, which present endogenously synthesized antigens to CD8+ 
cytotoxic T cells. HLA class I molecules are heterodimers consisting of a 
single transmembrane polypeptide chain (the -chain) and a ß2-
microglobulin (not encoded in the MHC) (204). The transmembrane              
-chain has three polymorphic domains (1, 2, 3) and each alpha-chain 
gene can be any one of 90–500 different alleles. HLA class I molecules are 
expressed on most nucleated cells of the body. 
MHC class II genes 
MHC class II genes include the genes for HLA-DR, DQ and DP molecules, 
which present exogenously derived antigens to CD4+ T cells. HLA class II 
molecules are expressed on cell surfaces as heterodimers consisting of α and 
ß chains. Both the α and ß can be polymorphic, although the ß chains are 
more polymorphic. HLA class II molecules are expressed B cells, DCs and 
macrophages. 
MHC class III genes 
The MHC class III region lies between class II and class I. It does not 
contain genes encoding HLA molecules, but contains genes encoding 
molecules with immunological function, including the genes for complement 
components C4A and C4B, C2 and factor B, and the genes for tumor 
necrosis factor (TNF). 
The complement system 
Complement was first identified as a heat-labile component of serum that 
augmented or “complemented” the anti-bacterial activity of antibody. The 
complement system consists of more than 30 plasma and cell-surface bound 
proteins, which react with one another to opsonize pathogens and induce 
inflammatory responses. 
Complement contributes to host defence by providing a rapid response to 
bacterial infections, by bridging innate and adaptive immune responses and 
by promoting clearance of apoptotic cells and immune complexes (ICs) 
(206, 207) (Table 3).  
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Table 2. Main biological functions of the complement system. 
Physiological role of complement 
1. Host defence against infections - Opsonization 
 - Lysis of bacterial cells 
 - Chemotaxis and activation of leukocytes 
 - Anaphylatoxin effects 
2. Bridging innate and adaptive immunity - Augmentation of antibody responses 
 - Enhancement of immunological memory 
3. Disposal of waste - Clearance of apoptotic cells 
 - Clearance of immune complexes 
Activation pathways of the complement system 
The complement system can be activated by different stimuli through three 
pathways; the classical pathway, the mannan-binding lectin or MBL 
pathway and the alternative pathway (Figure 3). 
Activation of the first component of each pathway initiates an enzymatic 
cascade through which complement components are sequentially cleaved, 
generating a large and a small fragment, that mediate biological functions. 
The large fragment remains surface bound and mediates two functions. It has 
proteolytic activity and continues the enzymatic activation cascade, and 
serves as an opsonin that marks the target for uptake by phagocytes. The 
smaller fragments are released and mediate chemotaxis and anaphylatoxin 
effects (208, 209). 
 
The classical pathway of complement activation 
The classical pathway is initiated by binding of the C1 complex to antibody 
(IgG and IgM) or directly to pathogen surfaces. C1 is a complex consisting 
of a single C1q molecule which has six globular heads with long collagen 
tails that combine to bind to two molecules of C1r, and two molecules of 
C1s, which are zymogens (210). 
Binding of C1q to the Fc portion of antibody causes a conformational 
change in C1r enabling cleavage of C1s, thus initiating activation of the         
classical pathway enzymatic cascade. Once activated C1s cleaves the next 
components of the classical pathway, C4 and C2. 
C4 is cleaved to form C4b and C4a. C4b is covalently bound to the target 
surface and recruits C2 making it susceptible to cleavage by C1s. C2 is 
cleaved to generate C2a and C2b. C2a is joined to C4b on the target surface 
to form the C3 convertase, C4bC2a, which cleaves C3 generating C3b and 
C3a. C3b is deposited onto the target surface to join the C4bC2a convertase 
to from the C5 convertase, C4bC2aC3b, which cleaves C5 to generate C5b 
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and C5a. Formation of C5b initiates the terminal complement pathway. The 
small fragments C4a, C3a and C5a are released. 
The MBL pathway of complement activation 
The MBL pathway is initiated by binding of the MBL complex to certain 
sugar residues on the pathogen surfaces and to apoptotic and necrotic cells 
(211). 
MBL belongs to the collectin family of C-type lectins that function as 
pattern recognition proteins and provide first line of immune defence. 
Collectins are characterized by a carbohydrate recognition domain (CRD) 
and a collagenous tail (212). The structure and function of MBL is similar to 
C1q. 
MBL consists of 2 to 6 carbohydrate-binding globular heads, containing 
CRD and a collagen stalk connected to 2 MBL-associated serine proteases, 
MASP-1 and MASP-2. Binding of MBL to carbohydrates activates             
MASP-2, which cleaves C4 and C2. At this point the MBL pathway 
converges with the classical pathway (213). 
The alternative pathway of complement activation 
The alternative pathway is initiated by spontaneous hydrolysis of C3 leading 
to formation of C3(H20) and the binding of C3b to hydroxyl groups on cell 
surface carbohydrates and proteins. C3(H20) forms a complex with factor B, 
a protein homologous to C2 and making factor B susceptible to cleavage by 
Factor D. Factor B is cleaved to generate Bb and Ba. 
Bb remains bound to C3b on the target surface to form the alternative 
pathway C3 convertase, C3bBb, which is able to cleave many C3 molecules 
to C3b forming an amplification loop for generation of C3b. C3b joined to 
C3bBb forms the alternative pathway C5 convertase, C3bBbC3b. 
The C3 convertases 
The C3 convertases, C4bC2a and C3bBb are powerful amplifiers of 
complement activation and up to 1000 C3 molecules are cleaved to C3b by 
each molecule of active C3 convertase. 
The terminal complement pathway 
All three pathways lead to cleavage of C5 and initiation of the terminal 
pathway. The C5 convertases, C4bC2aC3b and C3bBbC3b, cleave C5 to 
generate C5b and C5a. 
C5b is deposited on the pathogen surface and recruits C6, C7 and C8 
exposing hydrophobic domains that insert into the lipid bilayer of the cell. 
The C5b678 complex catalyses polymerization of the final component, C9, 
to form the membrane-attack complex (MAC) leading to lysis of the cell.  
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Figure 3. The complement system.  
Biological effects of complement 
C3b and C4b deposited on pathogen surfaces and ICs are opsonins that mark 
the targets for clearance from circulation and uptake by phagocytes. C3b and 
C4b are ligands for complement receptors expressed on phagocytes and red 
blood cells. 
On the target surface, C3b undergoes further cleavage to generate iC3b 
(inactive) and C3d and C3dg. C3b, iC3b, C3d and C4b are ligands for 
complement receptors on phagocytes and red blood cells. 
The smaller fragments generated, C4a, C3a and C5a, are peptide 
mediators of inflammation. They are all anaphylatoxins. C5a is more potent 
than C3a, which is more active than C4a. They act directly on local blood 
vessels, stimulate increased blood flow and vascular permeability, induce 
smooth muscle contraction, and increase binding of phagocytes to 
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endothelial cells. C5a acts directly on neutrophils and monocytes to increase 
their adhesion to vessel walls, their migration towards antigen and their 
ability to ingest particles and increases expression of CR1 and CR3 on these 
cells. C5a furthermore activates mast cells to release mediators such as 
histamine and TNFα (214). 
Complement receptors 
Specific complement receptors provide the link between activated 
complement components and various cell types.  
Complement receptor 1 (CR1) 
CR1 (CD35) is widely expressed and is found on erythrocytes, macrophages 
and monocytes, neutrophils, leukocytes, B cells and DCs. CR1 binds to C3b, 
C4b and iC3b and probably also C1q (215).  
CR1 on erythrocytes mediate clearance of ICs via binding to C3b and 
C4b on ICs facilitating their transport to the reticuloendothelial system 
where ICs are taken up by phagocytes. 
CR1 plays a role in regulating complement activation by inhibiting C3 
convertase activity (216). 
CR1 on macrophages and neutrophils can trigger phagocytosis on cells 
recruited by C5a. 
Complement receptor 2 (CR2) 
CR2 (CD21) is expressed on B cells, follicular DCs and some epithelial 
cells. CR2 binds iC3b, C3d or C3dg. 
On B cells, CR2 is part of the B cell co-receptor complex (CR2-CD19-
CD81) and binding of iC3b, C3d and C3dg to CR2 is thought to provide a 
link between the BCR and opsonized ICs, resulting in an enhanced B cell 
response to the antigen. CR2 binding to iC3b or C3dg opsonized ICs traps 
them in germinal centers where the antigen is displayed to activated B cells. 
Immature B cells in the marrow encounter antigen bound to C3d via binding 
to CR2 inducing B cell anergy. CR2 serves as a receptor for EBV (217). 
Complement receptor 3 (CR3) and complement receptor 4 (CR4) 
CR3 and CR4 are related receptors which bind iC3b and are found on 
monocytes/macrophages and neutrophils. They trigger phagocytosis of 
opsonized particles, either in concert with Fc receptors or independently. 
Phagocytosis of microorganisms via CR3, CR1 and FcR, is a major defence 
mechanism against bacterial and fungal infection.  
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Regulation of complement activation 
Because of the potent inflammatory effect of activated complement, the 
regulatory mechanisms of complement activation are finely balanced to 
ensure that activation is restricted to surfaces of opsonized targets and to 
hinder deposition of complement fragments on self cells and tissues (206, 
207). Regulatory mechanisms act at some key points and about half of the 
proteins of the complement pathways are regulatory proteins. 
Regulation of C1 
C1 inhibitor (C1-INH) regulates the activity of C1 by blocking proteolytic 
activity of C1r and C1s by mimicking their normal substrates, thus limiting 
cleavage of C4 and C2 and formation of the classical pathway C3 
convertase. 
C1-INH also binds free C1 in serum and inhibits spontaneous activation 
of C1. 
Limitation of C3 convertases 
The lifetime and activity of C3 convertase is regulated by several inhibitory 
proteins in all pathways. 
- Factor I, a serine protease that cleaves C3b, C4b and their breakdown 
products inhibits formation of C3 and C5 convertase. Factor I is regulated by 
membrane bound and fluid-phase cofactors: 
- Membrane bound cofactor protein (MCP) binds C3b and C4b monomers 
and facilitates factor I mediated proteolysis. 
- C4 binding protein (C4BP) (acts on C4bC2a) and factor H (acts on 
C3bBb), which catalyze the permanent inactivation of C3b and C4b via 
proteolytic cleavage by factor I and Decay Accelerating Factor (DAF).  
- CR1 promotes dissociation of the C3 convertases by binding to and 
displacing covalently bound C4b or C3b.  
Inactivation of C3b and C4b 
The reactive thioester bond in C4b and C3b must react with hydroxyl or 
amino groups to form covalent linkage to target surface. If this bond is not 
formed rapidly, C4b and C3b are cleaved by hydrolysis and inactivated.  
Regulation of the terminal pathway MAC 
Regulation of terminal pathway MAC and excessive cell lysis is mediated by 
membrane bound and plasma inhibitors. 
- The membrane bound CD59 inhibits MAC formation by binding to C8 
and C9. 
- S-protein and clusterin bind soluble C5-7 complexes or C8 and C9 and 
prevent their insertion into host cells. 
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Restriction of complement activation to pathogens 
Deposition of complement on normal cells is limited by several key 
inhibitors, but promoted on pathogen surfaces. 
Complement activation is selectively inhibited on host cells, which 
express CR1, DAF, MCP and CD59 and favor binding of factor H, 
mediating the dissociation of C3 convertase. These regulatory proteins are 
not expressed on pathogen surfaces. 
The complement system and disease  
Deficiency of complement components has been associated with 
autoimmune and infectious diseases. 
Complete deficiency of the early classical pathway components, C1, C4 
and C2, is strongly associated with increased susceptibility to SLE (206, 
215).  
MBL deficiency or low serum MBL levels are associated with increased 
frequency of infections and have also been associated with SLE as a minor 
risk factor (170, 172, 174, 218-224). 
Deficiency of C3 is associated with membranoproliferative 
glomerulonephritis and is also related to bacterial infections. 
Deficiency of the terminal complement pathway components (C5-C9) is 
associated with bacterial infections due to lack of cell lysis. 
When the regulatory mechanisms of complement activation fail, the 
complement system may have severe effects due to over-activation of 
complement. Defective regulation of C3 is typically associated with 
glomerulonephritis. Hereditary C1-INH deficiency is associated with 
angioedema. 
Complement deficiency in SLE 
Mouse models 
Mice deficient for C1q or C4 develop autoimmune diseases similar to SLE, 
displaying autoantibodies and SLE-like clinical manifestations (216, 225). 
C1q-/- mice exhibit glomerulonephritis characterized by multiple 
apoptotic cell bodies and immune deposits, suggesting that C1q deficiency 
causes autoimmunity by impaired clearance of apoptotic cells (226, 227). 
C4-/- mice display impaired clearance of circulating ICs which has been 
suggested as a causal mechanism in the development of a lupus-like 
autoimmunity phenotype (228). 
C3-/-C4-/- mice develop a SLE autoimmune phenotype, whereas C3-/- 
with C4+/+ mice do not. This may taken to suggest that it is the absence of 
C4 that predisposes to SLE (229). 
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Mice deficient for MBL display defective clearance of apoptotic cell, but 
no autoimmune phenotype (230). 
Complement deficiency and SLE in humans 
Complete (homozygous) deficiency of early classical pathway components, 
C1, C4, and C2 and MBL, has been associated with SLE. 
A hierarchical association is seen between deficiency of classical pathway 
components and SLE depending on the position within the sequence of 
complement activation, with the earlier components being associated with a 
higher frequency of SLE (C1 > C4 > C2) (231) (232) (Figure 4). 
 
Figure 4. A hierarchical association of complete complement deficiency with SLE. 
Adapted from Lewis 2006 (232). 
Complete complement deficiency is rare. However, partial deficiency of 
some complement components is more common, but whether partial 
deficiency predisposes to SLE in a similar or dose dependent way has been 
questioned. 
In SLE, deficiency of the early classical complement components is 
paradoxical. On the one hand, deficiency leads to decreased clearance of ICs 
and apoptotic cell debris harboring auto-antigens. On the other hand, 
complement mediates inflammatory responses at sites of IC fallout causing 
tissue injury.  
Papers I and II describe the association of C4AQ0 with SLE. 
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Complement mediated clearance  
of apoptotic cells and immune complexes 
Complement mediated clearance of apoptotic cells 
Apoptotic cells undergo morphological changes including nuclear chromatin 
condensation, DNA fragmentation, surface blebbing and formation of 
membrane bound debris (apoptotic debris). Under normal circumstance 
apoptotic cells are removed quickly by means of phagocytosis before they 
spill their intracellular content, which includes potential lupus antigens (233).  
Complement mediated clearance of apoptotic cells is mediated mainly by 
C1q, but MBL is also able to bind to apoptotic cells. C1q and MBL are able 
to bind directly to apoptotic cells via their globular head domains. C4b and 
C3b are deposited on the apoptotic cell and mediate binding to phagocytes 
via complement receptors (207, 231). Apoptotic cells are engulfed and their 
contents degraded. 
Deficiency of C1q may lead to decreased clearance of apoptotic cell debris, 
which has been suggested as the auto-antigen driving force in SLE (231, 234). 
Complement mediated clearance of immune complexes 
One of the imperative physiological roles of complement is to promote 
clearance of ICs. ICs are produced whenever there is an antibody response to 
soluble antigen. As the immune response progresses larger ICs are formed 
that are able to activate the complement system. Clearance is mediated 
mainly by the classical pathway via binding of C1q to the immunoglobulin 
portion of ICs with subsequent opsonization of ICs with C3b and C4b (216). 
As ligands for CR1, C3b and C4b mediate binding of ICs to erythrocytes. 
ICs bound to erythrocytes are transported to the reticuloendothelial system 
where they are taken up by resident phagocytes via binding to CR3 and CR4 
and FcR (Figure 5). 
Complement furthermore inhibits precipitation of ICs by solubilizing 
immune aggregates. C1q binds to the antibody portion of ICs and interferes 
with antigen-antibody interaction thus decreasing the size of ICs, facilitating 
their clearance (235, 236). 
 
Figure 5. Complement mediated clearance of ICs. 
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Impaired clearance of immune complexes has been associated with 
complement deficiency, in particular with deficiency of C2 and C4, which 
are strong risk factors for SLE. C4 and C2 deficiency may lead to decreased 
production of the classical pathway C3 convertase, C2aC4b and decreased 
cleavage of C3 with decreased opsonization of ICs with C3b and C4b (in C4 
deficiency) resulting in decreased binding of ICs to erythrocytes and 
insufficient transport of ICs to the reticuloendothelial system and subsequent 
accumulation of ICs in peripheral tissues. 
Deposition of ICs in peripheral tissues may lead to inflammation and 
tissue damage with increased release of autoantigens. This may initiate the 
cycle of enhanced autoantibody production, decreased clearance and 
deposition of ICs, inflammation and tissue damage (237). 
Inflammatory damage may expose cryptic autoantigens and activate 
autoreactive T and B cells. In addition, abundant ICs may enhance antigen 
uptake and activation by APCs, promoting lymphocyte activation, release of 
inflammatory cytokines, and the abrogation of anergy (238). 
The complement system and self-tolerance 
Loss of self-tolerance - impaired complement mediated clearance of 
apoptotic cells 
Normally in peripheral tissues, apoptotic cells are cleared very early by 
tissue macrophages, which produce anti-inflammatory cytokines and 
downregulate the antigen presentation function of DCs. It has also been 
suggested that immature DCs that have taken up apoptotic cells receive 
signals from the apoptotic cell, possibly via CR3, that inhibit development of 
antigen-presenting function of the DC (239, 240). The DC is thus not able to 
present self-antigens harboured  in the apoptotic cell to autoreactive T cells 
and self-tolerance is preserved. 
In complement deficiency states, where apoptotic cells and ICs are not 
cleared there is both an abundant amount of autoantigens for uptake by DCs 
and there is also an ongoing inflammatory response or danger milieu. 
Danger signals, such as pro-inflammatory cytokines, which stimulate DC 
maturation and activate macrophages, induce maturation of immature 
macrophages to DCs capable of antigen presentation to autoreactive T cells 
(232, 241). 
Furthermore, it has been suggested that non-cleared apoptotic cells may 
undergo secondary necrosis. Necrotic cells are capable of stimulating 
secretion of pro-inflammatory cytokines by macrophages (239, 242). This is 
though controversial. 
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Loss of self tolerance in B cells 
Self-tolerance in B cells is induced through negative selection of autoreactive 
B cells in the bone marrow, where autoreactive B cells encounter their 
cognate antigen leading to clonal deletion or anergy. Deficiency of C4 or 
CR1/CR2 has been hypothesized to lead to reduced negative selection of 
autoreactive B cells and impaired humoral responses (228). 
The theory suggests that complement targets self-antigens to the bone 
marrow and peripheral lymphoid compartments, ensuring their localization 
and provision. Self-antigens opsonized with C3d are bound to the BCR via 
CR2 and autoreactive B cells are deleted or rendered anergic and self-
tolerance is preserved (243). 
Deficiency of C1, C4 and C2, would lead to decreased opsonization of target 
autoantigens with C3d and diminished localization of autoantigens in the bone 
marrow. Immature B cells recognizing self-antigens would not encounter their 
cognate antigen and would not be deleted or anergized. The same line of 
thinking would apply for deficiency of CR2, which would lead to impaired 
binding of the C3d-bound self-antigen to immature B cells via the BCR. 
Complement component 4 (C4) 
The C4 gene 
The gene for C4 on chromosome 6 has been duplicated in humans and 
occurs as two genes, C4A and C4B that show 99% homology. The genes for 
C4A and C4B are arranged in tandem loci lying ∼10 kb apart. Each human 
C4 gene consists of 41 exons. 
Dichotomous size of C4 genes 
The C4 genes are dichotomous in size and are either long (20.6 kb) or short 
(14.2 kb), depending on the presence of a 6.5 kb retroviral insert HERV-K 
(human endogeneous retrovirus) in intron 9. C4A genes are consistently 
long, while C4B genes can be either long or short and have the retroviral 
insert present in a 2:1 ratio (244, 245). 
Duplication of C4 genes 
Duplication of C4 genes occurs in modular fashion together with the genes 
RP1/RP2 (Ser/Thre nuclear protein kinase), CYP1/CYP2 (steroid 21 
hydroxylase) and TNXA/TNXB (extracellular matrix protein X), which 
together with the C4 genes, constitute the RCCX genetic module. 
RCCX is found in mono-, bi-, and trimodular form containing 1, 2 or 3 
copies of C4 genes (80, 246) (Figure 6). 
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Figure 6. The RCCX genetic module with 1,2 and 3 copies of C4 genes. 
The C4 protein 
C4A and C4B protein allotypes 
Human C4 is the most polymorphic protein of the complement system and 
>41 alleles have been identified including null alleles for both C4A 
(C4AQ0) and C4B (C4BQ0) (244, 247, 248). 
Functional differences of C4A and C4B protein are attributed to 
differential activities of an internal thioester bond or thioester carbonyl 
group. The basis of the differing reactivities lies in four amino acid residues 
at positions 1101, 1102, 1105 and 1106, located in the C4d region of the C4 
genes (249). 
The C4A isotypic residues modulate activity of the reactivity of the 
thioester bond of activated C4A molecule to efficiently form a covalent 
amide bond. C4A binds more readily to amino groups, such as those found 
on ICs and amino-rich antigens (250). 
The C4B isotypic residues catalyze the formation of a covalent ester bond 
between the thioester carbonyl of activated C4B and hydroxyl groups. C4B 
binds more readily to hydroxyl groups and therefore has more hemolytic 
activity (251). 
In plasma, C4 consists of three polypeptide chains, α, β and γ and is 
encoded as a single-chain precursor with polypeptides in the order 
β, α, γ. The products (1725 amino acids) of the C4A and C4B genes differ 
by less than 1%. 
Deficiency of C4A (C4AQ0) 
Complete deficiency of C4 requires homozygote null alleles for both C4A 
(C4AQ0) and C4B (C4BQ0). Complete deficiency of C4 is strongly 
associated with SLE and lupus-like manifestations (232, 252, 253). 
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Partial deficiency of C4 due to C4AQ0 has been associated with SLE (6, 
254-256) and at least one C4AQ0 allele has been found in up to 50% or 
more of SLE patients and homozygosity for C4AQ0 is reported in 11-13% 
of SLE patients (257). In Icelandic SLE patients the frequency of C4AQ0 is 
50% compared to 25% in the population (254, 255). 
C4AQ0 is primarily associated with SLE, but has also been reported in 
primary Sjögren´s syndrome (258), autoimmune hepatitis (259), type 1 
diabetes (260, 261) and systemic sclerosis (SSc) (262). 
C4AQ0 alleles have been identified in varying frequency in most 
populations; 20-25% in Caucasians (254, 263, 264), 25% in Koreans (265), 
1,5% in Malaysians (266), but not found in a control group of Thais (267). 
Molecular basis of C4AQ0 
C4AQ0 defines C4A protein deficiency as determined by protein 
electrophoresis, irrespective of the underlying genetic change. The molecular 
basis for C4AQ0 differs from one racial group to another and even within 
the same ethnic groups. 
Among known genetic mechanisms for C4AQ are deletion of the C4A 
gene (252), deleterious mutations in exon 20 and 29 (252, 267-269), gene 
conversion at the C4A locus rendering the C4A genes to encode a C4B-like 
protein (270) and copy number variation, which may be related to the       
mono-, bi- and trimodular structures of RCCX (205).  
C4AQ0 and the MHC 
The location of the C4A gene within the MHC and the linkage 
disequilibrium among MHC genes has made it difficult to verify association 
of C4AQ0 with SLE susceptibility. 
Whether C4AQ0 is directly associated with SLE or is a marker reflecting 
another disease allele within the MHC has been debated. Family based 
studies identifying MCH haplotypes associated with C4AQ0 have helped in 
assessing the strength of the association of C4AQ0 with SLE. To deduce 
with greater certainty an independent association of C4AQ0 with SLE 
analysis of the genetic mechanisms underlying the null alleles is important.  
Mannan-binding lectin (MBL) 
The MBL2 gene  
The MBL2 gene encoding MBL lies on chromosome 10. The gene consists 
of four exons interrupted by three introns. Exon 1 encodes the signal peptide, 
exon 3 encodes a neck region and exon 4 a CRD, the region that recognizes 
not only microbial carbohydrates, but also molecular structures on dying 
host cells, including nucleic acids. The promoter sequence of the MLB2 
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gene contains several consensus elements, which are believed to regulate the 
vast majority of the gene expression (271, 272). 
The MBL protein  
MBL is an oligomer C-type lectin made up of two to six triple helices with 
collagenous tails that are cross-linked and coiled together and globular heads 
that contain carbohydrate recognition domains (CRDs). MBL must be 
polymeric to be optimally functional and monomers are not able to activate 
the complement system. The affinity of a single CRD is quite low and high-
affinity binding requires that several CRDs bind appropriate carbohydrate 
residues in a three dimensional pattern (273). 
Deficiency of MBL 
Polymorphisms in the MBL2 gene (variant alleles), both in the regions 
encoding the protein itself as well as in the promoter region have been 
shown to affect serum MBL levels. 
The variant MBL alleles are common worldwide, and around 3% of 
Caucasians are homozygous and a third heterozygous for one of the variant 
structural alleles (173, 274). In an Icelandic control cohort, the frequency of 
MBL variant alleles is 33% (171). 
Exon 1 minor alleles 
Three common polymorphisms at different loci in exon 1 of the MBL2 gene 
are correlated with low MBL serum levels (<1000 μg/L); minor or variant 
alleles B (codon 54), C (codon 57) and D (codon 52). 
The variant alleles B, C and D, commonly referred 0 alleles, result in an 
amino acid substitutions that can interfere with polymeric assembly of the 
MBL monomers. 
All three variant alleles have a profound effect on MBL serum levels, with 
a decrease in the level of functional MBL by up to 90%, even in heterozygous 
individuals. The effect of the D allele in heterozygotes is less than that of the 
B or C alleles. Homozygosity of or combinations of 0/0 minor alleles results 
in almost complete deficiency of serum MBL (275, 276). 
The wild type A allele is associated with high MBL serum levels (>1000 
μg/L). 
Promoter region polymorphisms 
Low MBL serum levels can also be associated with the L and X 
polymorphism in the promoter region of the MBL2 gene. 
H and Y promoter polymorphisms are associated with higher MBL levels 
(275, 276). 
P/Q promoter polymorphism does not affect serum MBL levels (273). 
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Co-stimulatory pathways  
of T cell activation and inhibition 
According to the two-signal model, full activation of T cells requires two 
signals. The first signal is antigen-specific and is provided by the interaction 
of antigenic-peptide MHC molecules on APCs with the TCR. The second 
signal is antigen independent and is provided by the interaction of 
co-stimulatory molecules expressed on APCs and T cell co-receptors (277). 
The B7 family of co-receptors 
The B7 family of co-receptors are structurally related type I membrane 
proteins that regulate immune responses in balanced cooperation via three 
main pathways, the CD28:CTLA4 pathway, ICOS:LICOS interactions and 
the PD-1 pathway (277-279) (Figure 7). 
 
Figure 7. B7 family T cell co-receptors and their APC ligands.  
The CD28:CTLA4 pathway 
The best characterized of the B7 family co-stimulatory pathways, so far, is 
the CD28:CTLA4 pathway, which involves interaction of the CD80 and 
CD86 ligands system on APCs with CD28 and CTLA4 on T cells.                   
Co-stimulatory signals for T cells activation are delivered via CD28 and                
co-inhibitory signals via CTLA4. CD28 and CTLA4 compete for binding to 
their APC ligands CD80 and CD86. CTLA4 has greater affinity for CD80 
and CD86 than CD28. 
CD28 is expressed on T cells and provides co-stimulation signals required 
for full T cell activation. CD28 is up-regulated on T cells after encounter 
with antigen and binds to CD80 and CD86, delivering the second signal 
necessary for T cell proliferation, cytokine production and prolonged T cell 
survival (280). 
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CTLA4 is rapidly expressed on T cells following activation and is highly 
upregulated by CD28 engagement. Ligation of CTLA4 antagonizes CD28 
mediated T cell stimulation, leading to decreased IL-2 production, inhibition 
of cell cycle progression and modulation of TCR signaling (281, 282). 
CTLA4 plays an important role in preventing autoimmune diseases by 
promoting long-lived anergy (280). 
The critical role of CTLA4 is evident in CTLA4-/- mice, which develop 
lymphoproliferative disease and die within 3-4 weeks after birth (283). In 
humans, polymorphisms in the CTLA4 gene have been implicated in 
susceptibility to several autoimmune diseases including SLE, RA, type 1 
diabetes, myasthenia gravis, coeliac disease and SSc (277, 280, 284-286). 
CTLA4-Ig, an antagonist of the CD28/B7 co-stimulatory interaction is 
now in clinical use (Abatacept) for RA patients. CTLA4-Ig is also a potential 
beneficial drug for SLE patients and has been shown to effectively prevent 
SLE onset in several murine models and to induce remission of active SLE 
nephritis (287). 
ICOS:LICOS interaction 
ICOS (Inducible co-stimulator) is expressed on activated T cells and shares 
several structural and functional similarities with CD28. Like CD28, ICOS 
has potent co-stimulatory effects on T cell proliferation and production of 
cytokines. ICOS is also important for germinal centers formation and clonal 
expansion of T cells (277, 288).  
The PD-1 pathway 
The PD-1 pathway consists of the PD-1 receptor and its APC ligands, PD-L1 
and PD-L2. PD-1 mediates inhibitory signals which downregulate T and B 
cell activation (82). 
PD-1 is expressed on T cells, B cells, natural killer cells, monocytes and 
myeloid DCs. PD-1 is not expressed on resting T cells, but is inducibly 
expressed after activation (289). PD-1 is inducibly expressed on APCs and 
monocytes, but its function on these cells in not clear (290).  
PD-1 is structurally related to CTLA4. The widespread expression of PD-1 
suggests that, compared to CTLA4, it may have a broader effect in regulating 
immune responses. Signalling through PD-1 limits T cells function including 
IFN-γ production, proliferation and increased apoptosis (291). 
The PD-1 ligands differ in expression. PD-L1 is highly expressed on 
monocytes and found on plasmacytoid and myeloid DCs and T cells and is 
also expressed on a wide range of non-hematopoietic cells. PD-L1 is 
upregulated by type I and type II interferons (292). PD-L2 expression is 
more restricted and PD-L2 is inducibly expressed on DCs, macrophages, and 
bone marrow derived mast cells. 
The CD28/CTLA4 ligand CD80 was recently identified as a binding 
partner for PD-L1 (293). 
 29
The PD-1 pathway 
The PDCD1 gene  
The PDCD1 gene on chromosome 2q37 consists of 5 exons, exon 1 encodes 
a short signal sequence, exon 2 an Ig domain, exon 3 the stalk and 
transmembrane region, exon 4 encodes the start of the cytoplasmic domain 
and exon 5 the C-terminal intracellular residues and a long 3´UTR. 
Splice variants of the PDCD1 gene have been cloned from activated T 
cells, yielding transcripts lacking exon 2, exon 3, exons 2 and 3 or exons 2, 3 
and 4. All transcripts except for the splice variant lacking exon 3 are 
expressed as full length PD-1 in resting PBMCs and are all increased in 
expression upon activation of T cells with αCD3 and αCD28 (294). 
The PD-1 receptor  
The protein structure of PD-1 includes an extracellular Ig domain followed 
by a transmembrane region and an intracellular tail, which contains two 
phosphorylation sites. The most membrane proximal tyrosine is located in an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) and the distal 
tyrosine is located in an immunoreceptor tyrosine-based switch motif 
(ITSM). 
During cellular activation, the tyrosine residue of the ITIM motif is 
phosphorylated by the Src homology 2 protein tyrosine phosphatase 2. This 
leads to deactivation of downstream signaling molecules such as 
phosphatidylinositol 3-kinase, dephosphorylation of downstream signaling 
molecules and activation of the Ras/Raf/MEK/Erk pathway leading to 
G0/G1 cell cycle arrest, providing peripheral control of continued cellular 
activation (295, 296). 
PDCD1 gene polymorphisms and autoimmune diseases 
Pdcd1-/- mouse models 
The important inhibitory function of PD-1 was first appreciated by the 
autoimmune-like phenotype of pdcd1/ mice, which provided the first 
evidence for PD-1 as a key player in autoimmunity (82, 297, 298). 
Pdcd1-/- mice with different genetic backgrounds all developed 
autoimmune disease with differing phenotypes. C57BL/6 mice with PD-1 
deficiency were found to have increased incidence of glomerulonephritis and 
exhibited arthritis, with synovial cell proliferation, lymphocyte infiltration, 
and pannus formation (297). The phenotypes resembled the clinical 
manifestations of SLE and RA in humans. In contrast, PD-1-deficient 
BALB/c mice developed autoimmune cardiomyopathy, with IgG deposition 
in the heart (298).  
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PD-1 gene polymorphisms in humans 
To date over 30 polymorphisms have been identified in the human PDCD1 
gene, some of which have been associated with different autoimmune 
diseases, including SLE (91, 93, 299), RA (84, 87, 92), type 1 diabetes (89, 
90, 300, 301), Graves´ disease (83, 88), ankylosing spondylitis (AS) (86), 
primary biliary cirrhosis (PBC) (302) and MS (85). 
The PD-1.3A polymorphism 
PD-1.3A was the first polymorphism in the PDCD1 gene to be associated 
with an autoimmune disease in humans (81).  
A genome scan in 8 Icelandic multicase SLE families identified five 
chromosomal regions with lod-scores indicative of possible linkage to SLE, 
among them 2q37. In 6 of the 8 families there was a high frequency of 
C4AQ0 (254) and the presence of C4AQ0 was the basis for stratification. 
The 2 families that do not have C4AQ0 were excluded from further analysis. 
This reduced heterogeneity for chromosome 6 alleles considerably and lod-
scores for a number of regions increased, in particular at 2q37 (69). 
The 2q37 region was replicated in Swedish multicase SLE families and a 
pooled analysis of the Icelandic and Swedish SLE family sets gave a 
combinational effect and a highly significant lod-score of 4.24. Fine 
mapping in the region indicated the location of the locus most likely to be 
associated with SLE. The locus was denoted as SLEB2 (303). 
The PD-1.3 polymorphism is a GA change. PD-1.3 is located in intron 
4 of the of the PDCD1 gene and is thought to alter a binding site of the runt-
related transcription factor (RUNX1/AML1), which modulates transcription 
of the PDCD1 gene, suggesting a mechanism through which it could 
contribute to the development of SLE in humans. 
The association of PD-1.3A with SLE has been replicated in SLE cohorts 
of different ethnicity. The association is strongest in Caucasian populations, 
but also found in other populations, for instance Mexican and African-
American SLE patients (77, 81, 93, 299, 304-306). PD-1.3A has, 
furthermore, been found to be associated with other autoimmune diseases, 
such as RA (84, 87, 92), type 1 diabetes (89, 90), MS (85), AS (86) and 
Graves´ disease (83, 88) (Table 4). 
There are, however, reported non-associations of the PD-1.3A allele with 
SLE and other autoimmune disease. In a Spanish cohort, a lower frequency of 
PD1.3A was found in SLE patients compared to population controls (307) 
and PD-1.3A was not associated with SLE in African-American patients (81). 
The discrepancies in association and non-association with autoimmune 
diseases may reflect ethnic differences. Geographical variation is, for 
instance, apparent in the frequency of the PD-1.3A allele across Europe, 
with decreasing frequency form north to south (77) demonstrating the 
importance of studying relatively homogeneous populations.  
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Table 3. A list of studies reporting association and non-association of PDCD1 gene 




polymorphism Association Population / Ethnicity Ref. no 
SLE PD-1.3A Yes Icelandic, Swedish (81) 
  Yes Mexican (81) 
  Yes European and African-American (305) 
  Yes Swedish (309) 
  Yes Caucasian (304) 
  Yes Northeast Europe (77) 
  No African-American (81) 
  No Spanish  (307) 
  No Southwest Europe (77) 
 Other Yes Danish (91). 
  Yes Taiwan (93) 
  Yes Hispanic (304) 
  Yes Polish  (299) 
  Yes Han Chinese (310) 
  No Taiwan (87) 
  No Asian (304) 
  No African-American (304) 
  No Polish  (299) 
RA PD-1.3A Yes Swedish (92) 
  No Japanese (311) 
 Other Yes Taiwan (87) 
  Yes/No Chinese (84) 
   No Japanese (311) 
Type 1 diabetes PD-1.3A Yes Danish (90) 
 Other Yes/No Japanese (301) 
  Yes Japanese (89). 
  No Swedish (312). 
  Unclear UK (313) 
Graves' disease Other Yes/No UK Caucasian (88). 
AS Other Yes Korean (86) 
MS PD-1.3A Yes German (85) 
PBC PD-1.3 A Yes USA (302) 
 
 
Taken together, there is accumulated evidence supporting association of 
different PDCD1 gene polymorphisms with SLE and other autoimmune 
diseases. 
 32 
To date, there is, to our knowledge, only one published study on cellular 
expression of the PD-1 receptor in humans (308). Paper III describes PD-1 
cellular expression on T cells in correlation to the PD-1.3A in Icelandic and 
Swedish SLE patients.  
Polymorphisms in the PD-ligand genes 
Studies on the association of polymorphism in the genes for PD-L1 and 
PD-L2 have shown controversial results, which may again reflect ethnic and 
population differences. 
The genes encoding PD-L1 and L2 are located in close proximity on 
chromosome 9p24. A genome scan of Icelandic multicase SLE families 
showed suggestive linkage to a marker located close to the PD-ligand genes. 
However, analysis of SNPs within the PD-ligand genes on Swedish, 
Mexican and Argentinean trios as well as independent sets of patients and 
controls from Sweden did not support genetic association of PD-ligands to 
SLE (314). A study on SLE patients in Taiwan, on the other hand, found that 
a PD-L2 gene polymorphism may be associated with susceptibility to SLE, 
but no significant association with PD-L1 polymorphisms was found (315). 
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The present investigation 
Aims 
 
• To study the genetic basis of C4A protein deficiency (C4AQ0) and 
its associated MHC haplotypes in Icelandic multicase SLE families. 
 
• To study the association of low MBL serum levels with SLE in 
Icelandic multicase SLE families having a C4AQ0 susceptibility 
background.  
 
• To study cellular expression levels of the PD-1 receptor on T cells in 
SLE patients, relatives and controls and correlate with the PD-1.3A 
polymorphism. 
 
• To study autoimmune diseases in Icelandic multicase SLE families 
and the association of three SLE susceptibility factors, C4AQ0,          


















The papers presented in this thesis are based on analysis of SLE patients and 
relatives from Icelandic multicase SLE families and Swedish SLE patients.  
 
• Paper I: Nine Icelandic multicase SLE families, 26 SLE patients and 
73 first- and 14 second-degree non-SLE relatives. 
• Paper II: Nine Icelandic multicase SLE families, 24 SLE patients, 83 
first- and 23 second-degree non-SLE relatives and as an ethnically 
and age matched control group, 24 unrelated family members 
(spouses and in-laws). 
• Paper III: Icelandic and Swedish SLE patients, their relatives and 
unrelated healthy non-autoimmune controls. In total 14 SLE 
patients, 7 relatives and 16 controls. 
• In paper IV: Eight Icelandic multicase SLE families, 23 SLE 
patients and 101 first- and second-degree relatives and population 
control cohorts. 
The number of SLE patients and relatives studied in the papers varies 
depending on life samples and clinical information available at the time of 
study.  
Icelandic multicase SLE families 
A multicase family is defined as a family with two or more affected 
individuals of third degree relation or less (Figure 8). Families 7 and 9 
include SLE patients of more distant relation. The patients with SLE fulfilled 
4 or more of the ACR 1982 classification criteria for SLE.  
The Icelandic multicase SLE families originate from different parts of the 
country and they vary in size. The two largest families originate from areas 
in Iceland that were geographically isolated up until the middle of the 20th 
century, in the North-West and East. 
Data for both the SLE patients and their relatives has been systematically 
collected; clinical data from hospital records and detailed information on 
autoimmune diseases based on diagnosis of rheumatologists. These families 
have furthermore been analyzed for immunological parameters; 
autoantibody profiles and complement component C4. 
Detailed genealogical information about Icelanders dating back as far as 
250-300 years is accessible, making it easy to trace ancestry and relations 
back several generations. Relations of 250 SLE patients diagnosed in Iceland 
from 1975 have identified multicase SLE families. Nine of them have been 
analyzed extensively and are the basis for several studies. 
The Icelandic population, of 320.000, is almost entirely Caucasian and is 
today still remarkably homogeneous. Most Icelanders are descendants of 
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Norwegian settlers and Celts from Ireland and Scotland brought over as 
slaves during the age of settlement (874-930). DNA analysis suggests that 
around 66% of the male settler-era population was of Norse ancestry, 




Figure 8. Pedigrees of Icelandic multicase SLE families. SLE patients are shown in 
black. 
Materials and methods 
Analysis of complement component C4 
C4 allotyping 
C4 allotypes were analyzed by high voltage agarose electrophoresis on 
caboxypeptidase (Sigma, Type I) and neuraminidase (Sigma, Type VIII) 
treated serum samples followed by immunofixation with monoclonal 
antibodies (Incstar). 
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C4A and C4B allotypes were determined by the relative intensities of 
C4A and C4B bands with visual inspection and comparison to control 
samples. Zygosity was corroborated using haplotype analysis. 
C4A deletion genotyping by long range PCR 
A novel long range PCR method was applied to detect deletion of the C4A 
gene. The method is based on two separate PCR assays, one deletion specific 
and one specific for non-deleted C4A genes as described by Grant, 
Kristjánsdóttir et al (317).  
A universal forward primer was used for both assays. The primer is located 
in the RP1 (G11) gene, which is the closest unique sequence to the C4A gene. 
A reverse primer in exon 10 of the C4A and C4B genes is specific for 
deleted C4A genes. The C4B1 gene, which is consistently found with C4A 
gene deletion is short and lacks the 6.5 HERV-K(C4) retroviral insert in 
intron 9. In case of a deleted C4A gene a 5.4kb PCR product is generated 
through amplification of the short C4B1 gene. In case of non-deleted C4A 
genes, which are long and contain the 6.5 viral insert, the expected 11.8 kb 
PCR product (C4A + C4B) would not be generated since it is too long for 
the reaction conditions.  
C4A genes are long and contain the retroviral insert in intron 9. Deleted 
C4A genes lack the insert. A reverse primer specific for non-deleted C4A 
genes anneals at the junction between HERV-K(C4) and the unique 
sequence of intron 9 and specifically detects non-deleted C4A genes. Non-
deleted C4A genes render a 5.2 kb PCR product. 
Each PCR reaction was carried out on 100 ng of genomic DNA in a total 
volume of 20 μl with 0.4 μM concentration of each primer, 200 μM dNTPs 
and components of the rTth DNA polymerase XL (Perkin Elmer), 1 mM 
Mg(OAc)2 universal and the associated buffer. Thermal cycling conditions 
were as follows: 94°C for 30s, followed by 35 cycles of 90°C for 10s, 55°C 
for 10s and 65°C for 10 min. The rTth polymerase mix has exonuclease 
activity and therefore the reaction was initiated immediately after its addition. 
The products underwent electrophoresis (in the presence of 0.25% 
bromophenol blue and 40% (w/v) sucrose) on a 0.8% agarose gel (Sigma) in 
Tris-borate-EDTA (TBE) buffer for 100 V/h.  
Screening for mutations in exons 20 and 29 of the C4A gene 
PCR methods were applied according to protocol to screen for a point 
mutation in exon 20 (318) and exon 29 (268) of the C4A gene.  
 37
Analysis of HLA alleles and construction of MHC haplotypes 
Typing of MHC class I and II alleles 
Typing of MCH class I HLA-B allotypes was performed on serum samples 
using the lymphocytotoxicity test (319) and typing of MHC class II HLA-
DR alleles by PCR with sequence specific primers (PCR-SSP) (Dynal) 
(320). Performed at the Blood Bank of Iceland at Landspítali-University 
Hospital, Reykjavík, Iceland. 
Construction of MHC haplotypes  
MHC haplotypes (HLA-B – C4A-C4B – HLA-DR) were constructed using 
pedigree information to verify typing results. For individuals with 
incomplete HLA or C4 typing, haplotypes were deduced form first-degree 
relatives. 
Analysis of MBL variant genotypes and serum levels 
Genotyping of MBL variant alleles 
A real time polymerase chain reaction (RT-PCR) was carried out in the 
LightCycler (Roche Diagnostics, Mannheim, Germany) (274). In brief, using 
temperature curve analysis the three mutant structural alleles B, C and D in 
exon 1 were detected in one reaction. The promoter polymorphisms HL 
and YX were detected in two reactions: H/L polymorphism by single-
color detection and the X/Y and P/Q polymorphisms using dual color probes 
in one capillary. Performed at the Department of Immunology, Landspítali-
University Hospital, Reykjavík, Iceland. 
Measurement of serum MBL levels 
A sandwich-ELISA was used to measure serum MBL levels (321). 
Microtiter wells were coated overnight at 4°C with monoclonal mouse anti-
human MBL antibody (SSI). Two dilutions of the test sera (1/25 and 1/200) 
were then incubated for 1 h at room temperature together with a serial 
dilution of a standard calibrated with highly purified MBL (SSI). Sera that 
were low in MBL were retested at 1/3 and 1/9 dilutions. Biotinylated Mab 
(1:8000) was then added for 1 h at room temperature followed by 
horseradish peroxidase labeled streptavidin (1:8000) (Sigma) for a further 1 
h at room temperature. After 5 min incubation with tetramethyl benzidine 
the reaction was stopped with 0.18 M H2SO4 and the absorbance read at 450 
nm. The microtiter wells were washed 3 times with PBS/0.5 M NaCl/0.5% 
Triton-X 100 after each step. Three control sera with low, medium and high 
MBL concentration were included in each test run to monitor assay 
variability. The lower detection limit of the assay was 20 μg/L. Serum MBL 
levels below 1000 μg/L were defined as low MBL levels. Performed at the 
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Department of Immunology, Landspítali-University Hospital, Reykjavík, 
Iceland. 
Analysis of PD-1 
Genotyping of PD-1.3 G/A 
PD-1.3 G and A alleles were distinguished using PCR followed by 
restriction fragment length polymorphism using PstI restriction enzyme. 
100ng genomic DNA was amplified in 50 μl reaction mixture (2-5μl 
DNA, 4μl dNTP, 10pmol each primer, 5μl 10X PCR Gold Buffer, 1.5mM 
MgCl2, 5U AmpliTaq Gold Polymerase (Applied Biosystems). The 
sequences of primers were: forward primer 5´ CCC CAG GCA GCA AGG 
TCA AT3´ and reverse primer: 5´ GAC CGC AGG CAG GCA CAT AT3´). 
The PCR conditions were: 10 min. at 95°C, followed by 45 cycles at 95°C 
for 15s, 60°C for 30s and 72°C for 15s and with a final extension for 5 min. 
at 72°C. PCR product was digested overnight at 37°C with 4U PstI 
restriction enzyme (New England Biolabs) and resolved on a 4% agarose 
gel. 
PstI cuts at GA sites leaving wild-type G alleles uncut resulting in a 180 
bp fragment and mutation A alleles cut resulting in 2 fragments of 150 and 
30 bp. 
Cellular expression of the PD-1 receptor 
Isolation, freezing and thawing of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA 
whole blood by standard density-gradient method using Ficoll-Paque (GE 
Healthcare Bio-Sciences AB) and suspended in RPMI-1640 media with 10% 
FCS. 
PBMCs were then cryopreserved in DMSO media containing 40% FCS 
and 20% DMSO. At the time of culture cells were thawed gently in 37°C 
water bath and transferred to culture media containing RPM1 1640 10% 
FCS. Cells were centrifuged and washed 2 times to remove DMSO and 
resuspended in culture media RPM1 1640 10% FCS and cell viability 
assessed by trypan blue count. 
Stimulation and culture of peripheral blood mononuclear cells 
PBMCs were stimulated with αCD3 and αCD28 antibodies (R&DSystems) 
using the following protocol: Culture plates were coated with 10μg/ml 
αCD3 antibodies and incubated for 3 hours at 37°C and then washed with 
PBS. 500 μl of 20μg/ml αCD28 in RPMI-1640 10% FCS media were added 
to each well along with 500μl of 1x106 cells/ml. Final concentration in 
culture wells was 10μg/ml αCD28 and 0.5x106 cells/ml. Cells were cultured 
at 37°C and 5% CO2 for 48 hours. 
 39
Flow cytometry 
Cell surface expression of markers was analyzed by flow cytometry. At t0 
and after 48 hours of culture cells were stained with fluorescent monoclonal 
antibodies against PD-1, CD3, CD4, CD8, CD25 and IgG isotype controls 
(BDPharmingen). Briefly, 100 μl of cells were added to tubes containing 
antibody cocktails and incubated on ice for 30 min. in the dark. The cells 
were then washed twice with PBS and finally resuspended in 0,5% 
paraformaldehyde. 
FoxP3 expression was analyzed by intracellular staining according to the 
manufacturers’ protocol using FoxP3 antibody and FoxP3 staining buffer set 
(Fixation/Permeabilization diluent and 10X Permeabilization buffer) 
(eBioscience). Briefly, surface-stained cells were resuspended in 1 ml of 
FoxP3 fixation/permeabilization buffer and incubated at room temperature in 
the dark for 30 min.. Following centrifugation cells were washed twice and 
then incubated for 20 min in FoxP3 permeabilization buffer. FoxP3 antibody 
or isotype control was added to the cells and incubated at 4°C for 30 min. in 
the dark. Cells were then washed twice in FoxP3 permeabilization buffer and 
finally resuspended in flow cytometry staining buffer (eBioscience). 
Cells were harvested on a FACSCalibur machine and 10000 cells 
collected per staining. FACS data was analyzed using FlowJo® software. 
Data is presented as the frequency or percentage of cells within analysis gate 
and geometric mean of fluorescence intensity (MFI) on a histogram. 
Evaluation of autoimmune diseases and autoantibody profiles 
Protocol for evaluation of autoimmune diseases 
Following a predefined protocol, involving interviews and physical 
examination and review of medical records by two rheumatologists, all 
family members were evaluated for the presence of SLE and autoimmune 
diseases. 
All SLE patients fulfilled 4 or more of the 1982 ACR classification 
criteria for SLE. Autoimmune disease refers to the diagnosis of autoimmune 
diseases other than SLE and does not include family members having only 
autoimmune manifestations not fulfilling criteria for an autoimmune disease 
or having only autoantibodies.  
Autoantibody profiles 
The following panel of autoantibodies was measured: ANA, ENA (RNP, 
Sm, SSA (Ro), SSB (La), Scl-70, centromere, Jo-1), anti-dsDNA, 
rheumatoid factor by agglutination and by an isotype specific ELISA (IgA, 
IgG, IgM), in addition to antibodies against striated and smooth muscle 
(SMA), mitochondria, thyroglobulin (TG), thyroid peroxidase (TPO), and 
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gastric parietal cells. Performed at the Department of Immunology, 
Landspítali-University Hospital, Reykjavík, Iceland. 
Statistical analysis 
• Paper II: For statistical comparison of the frequency of C4AQ0 and 
low MBL in groups of SLE patients, autoimmune and non-
autoimmune relatives and controls, p-values and odds ratios were 
calculated using Fisher´s exact test. Non-parametric tests were used 
for analysis of MBL serum levels as these do not fulfill normal 
distribution, Mann-Whitney Rank Sum test was used to compare 
two groups and Kruskal-Wallis Analysis of Variance on Ranks for 
comparison between three groups. All tests were two-sided and the 
level of significance was set at p < 0.05.  
• Paper III: The mean frequency of cells expressing PD-1, CD4, CD8 
and CD25 and the geometric mean of MFI was calculated for each 
SLE patient, relative and control. The mean value for the groups of 
SLE, relatives and controls were compared using paired t-test. 
Fisher’s exact test with two-tailed probability was used for 
comparison of groups and paired t-test for intra-sample comparison. 
Significance level was set at 0.05. 
• Paper IV: For statistical comparison of the frequency of PD-1.3A, 
C4AQ0 and low MBL in groups of SLE patients, autoimmune and 
non-autoimmune relatives and controls, p-values and odds ratios 
were calculated using Fisher´s exact test with two-tailed probability 








Background and aims 
C4AQ0 has been found in varying frequency on different MHC haplotypes 
in several ethnic groups. In Caucasians the most common C4AQ0 haplotype 
is the conserved HLA-B8-C4AQ0-C4B1-HLA-DR3 haplotype, which has 
been associated with a deletion of the C4A gene (254, 322-324). 
An earlier study on Icelandic multicase SLE families established an 
association of C4AQ0 with SLE. In this initial study, the frequency of C4AQ0 
(homo- and heterozygote) was found to be significantly increased in SLE 
patients (50%) compared to a population cohort (25%). In the same study, 
analysis of MHC haplotypes identified 12 C4AQ0 bearing haplotypes revealing 
weaker linkage of C4AQ0 with HLA-DR3 than reported in other studies (254). 
These results pointed to a heterogeneous genetic background for C4AQ0. 
In follow-up, the present study was undertaken with the aim to analyze the 
genetic basis of C4AQ0 with emphasis on determining the frequency of C4A 
gene deletion. Furthermore, to identify MHC haplotypes associated with the 
C4A deletion. 
C4 “null alleles” are defined by protein electrophoresis (247), relying on 
visual inspection of protein band intensities to identify heterozygous ”null 
alleles”. Homozygous “null alleles” are identified by the lack of a protein 
band. Detection of heterozygous “null alleles” may be inaccurate when 
relying only on protein band intensity and heterozygous “null alleles” may 
be missed and the frequency of C4AQ0 underestimated. In this study, a 
novel long range PCR (LR-PCR) method was applied to verify deletion of 
the C4A gene (317) (see materials and methods). 
Results 
Frequency of C4A protein deficiency (C4AQ0) 
Analyzed by protein electrophoresis the frequency of C4AQ0 was found to 
be 53,8% in the SLE patients and 47,9% in first- and 28,6% in second-
degree relatives. C4AQ0 homozygosity was found in 10,6% of the family 
members, 11,5% of the SLE patients and 12,3% of first-degree relatives. 
Frequency of C4A gene deletion 
LR-PCR analysis verified a C4A gene deletion as the genetic basis for 
C4AQ0 in 60,4% of the family members having C4AQ0, accounting for 
64,3% of C4AQ0 alleles in the SLE patients, 60,0% in first-degree and 
50,0% in second-degree relatives. 
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Based on LR-PCR results, discrepancies were revealed in our initial C4 
protein electrophoresis analysis of C4AQ0, which had not detected some 
heterozygous C4A ‘null alleles’. 
C4A gene deletion haplotypes 
Analysis of MHC haplotypes confirmed C4A gene deletion in association 
with the classical B8-C4AQ0-C4B1-DR3 haplotype, which was found in 6 
of the 9 families. The haplotype accounted for C4A deletion in 87,5% of 
family members; 88,9% in the SLE patients, 90,5% in first-degree and 
50,0% in the second degree relatives having C4AQ0.  
Furthermore, two variant forms of the classical C4A deletion haplotype 
were found to carry C4A deletion, one having DR7 instead of DR3 and one 
having B7 instead of B8. 
The DR7 variant haplotype was found in 4 family members in one family 
and accounted for 12,5% of C4A deletion. 
The B7 variant haplotype was found in 1 second-degree relative. The 
haplotype penetrated the family through marriage. 
Discussion 
A C4A gene deletion was found to be the genetic mechanism of 60% 
C4AQ0 alleles. Other, as yet undefined, genetic changes thus account for 
one-third of C4AQ0. Point mutations in exons 20 or 29 of the C4A gene 
were not found to account for C4AQ0.  
C4A gene deletion was found on 3 MHC haplotypes, further suggesting 
that C4AQ0 is independently associated with SLE and not a marker in 
linkage disequilibrium with other MHC alleles, such as HLA-DR3. In 
addition to the classical deletion haplotypes, two other haplotypes carry a 
C4A gene deletion. 
In summary, the data from our initial (254) and present studies confirm a 
heterogeneic background for C4AQ0 in association with different MHC 
haplotypes with varying HLA class I and II alleles. This is despite a strong 
disequilibrium among genes within the MHC. 
Original studies identifying association of C4AQ0 with SLE were 
criticized on the basis that the association was secondary to segregation of 
C4AQ0 with the HLA-B8-DR3 haplotype. However, C4AQ0 on varying 
MHC haplotypes has been found to be associated with SLE in different 
ethnic groups suggesting that the association is genuine (232). 
Taken together, our results give support for the hypothesis that C4AQ0 
may be an independent susceptibility factor for SLE, irrespective of the 
genetic basis for C4AQ0 and other MHC alleles. C4A protein deficiency 
may be one of several genetic factors contributing in unison with other 






Background and aims 
Low MBL serum levels have been associated with increased susceptibility to 
infections (176, 325) and to some extent with autoimmune diseases (326-
328). With two exceptions (329, 330), previous studies on different 
populations have shown association of low MBL with SLE (170, 172, 174, 
218-224). 
MBL deficiency is largely genetically determined and low MBL serum 
levels are correlated with polymorphisms in the MBL2 gene. Three common 
polymorphisms in exon 1, i.e. variant alleles B, C and D (designated 0) are 
correlated with low MBL serum levels (<1000μg/L). The wild type allele A 
is correlated with serum MBL levels >1000μg/L. Low MBL serum levels 
can also be associated with the L and X promoter region polymorphism, 
while the H and Y promoter polymorphisms are associated with higher MBL 
levels (275, 276). 
The aim of the study was to analyze the frequency of MBL variant alleles 
and serum MBL levels in the Icelandic multicase SLE families and 
determine whether low MBL confers increased risk of SLE independently or 
in the setting of C4AQ0. 
This is, to our knowledge, the first study analyzing whether low MBL 
confers increased risk for SLE in families that are predisposed to the disease. 
Results 
Correlation of MBL genotypes with MBL serum levels 
Low MBL genotypes, were strongly associated with low MBL serum levels 
(<1000 μg/l) and there was no evidence of MBL consumption in the SLE 
patients. MBL concentration of 1000 μg/l clearly distinguished between 
family members with and without low MBL genotypes.  
Frequency and distribution of low MBL genotypes and C4AQ0 in the 
families 
In the nine multicase families, low MBL genotypes were found in 38% of 
the SLE patients, 26% of first-degree and 13% of second-degree relatives 
and in 33% of the non-consanguineous family members compared to 33% in 
the population cohort. Thus, low MBL showed only a marginally significant 
trend for SLE in the nine families pooled. 
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However, C4AQ0 was significantly increased in frequency in seven of the 
nine families compared to population controls and was found in 50% of the 
SLE patients, 47% of first-degree and 39% of second-degree relatives 
compared to 25% in the population cohort. 
Analysis of “low MBL” families 
In the course of analyzing the data, it became apparent that the distribution 
of low MBL genotypes and low serum MBL levels was uneven and was 
restricted to five of the families. These five families are designated “low 
MBL families”. 
Analysis of the “low MBL families” showed a significantly higher 
frequency of low MBL genotypes in SLE patients compared to the relatives 
groups; 64% of the SLE patients, 38% of first-degree relatives, but none of 
the second-degree relatives had low MBL genotypes. 
In accordance with the increased frequency of low MBL genotypes in the 
SLE patients, serum MBL levels were also much lower in the SLE patients 
compared to first-degree and second-degree relatives. 
Frequency of the combination of C4AQ0 and low MBL  
The combination of C4AQ0 and low MBL was present in 36% of the SLE 
patients, 18% of first-degree relatives and no second degree relative and was 
significantly increased in frequency in the SLE patients compared to the 
relatives. 
Discussion 
When this paper was published, it was the first study on MBL in multicase 
SLE families. Our results for all of the nine families pooled, which showed 
that low MBL only tended to be associated with SLE, are in accordance with 
previous studies showing a weak association between low MBL and SLE. 
SLE patients had an increased frequency of variant MBL structural alleles in 
the MBL2 gene compared to their close relatives, and a trend of stepwise 
decrease from the patients to first-degree to second-degree relatives was 
significant. 
The families showed heterogeneity with regards to distribution of low 
MBL and when we stratified on the basis of low MBL, only five of the 
families were found to carry the low MBL genotypes and have low MBL 
serum levels. 
Stratification of the families for the presence of variant MBL alleles, 
however, gave results indicating that variant MBL alleles are a risk factor for 
SLE in predisposed families. In the “low MBL families”, low MBL was 
found to be significantly associated with SLE.  
Our conclusion is that MBL deficiency is not sufficient to cause SLE, but 
adds to SLE susceptibility in genetically susceptible individuals. An additive 
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effect of a combination of C4AQ0 and low MBL (219, 221) or low MBL 
and FcγR polymorphisms (113) has been reported. 
The Icelandic families have a predisposing genetic background of C4AQ0 
(254, 256) and the combination of C4AQ0 and low MBL genotypes was 
found to confer an additive effect in SLE susceptibility. C4AQ0 may be part 
of a predisposing background, on which low MBL or other susceptibility 
factors can trigger disease expression.  
The additive effects of C4AQ0 and low MBL support the hypothesis that 
multiple defects in the complement system can lead to accumulation of 
apoptotic debris and ICs, mediating autoimmune triggering, inflammation 







Background and aims 
The PDCD1 gene codes for the co-inhibitory immunoreceptor PD-1, 
suggested to play an important role in maintenance of peripheral self-
tolerance in T and B cells. 
PD-1.3A was the first PDCD1 gene polymorphism to be associated with 
autoimmune disease in humans. It was initially found to be associated with 
SLE in Icelandic and Swedish multicase SLE families and replicated in 
Mexican SLE families (81). More recently, these findings have been 
replicated in different populations (77, 93, 299, 304-306, 309). Moreover, 
other polymorphisms in the PDCD1 gene have been identified in SLE and 
other autoimmune diseases (81, 83, 86-88, 90, 92, 93, 307, 309). 
Pdcd1 knockout mice have been shown to develop an SLE-like disease 
(82, 297, 298) and hypotheses regarding to role of PD-1 in SLE and other 
autoimmune diseases in humans have, so far, been based on mouse models. 
The PD-1.3A allele is thought to disrupt the predicted DNA-binding site 
for the RUNX1 transcription factor and may lead to aberrant expression of 
the PDCD1 gene (81). 
The aim of the present study was to analyze cellular expression of the PD-
1 receptor in SLE patients, relatives and non-related healthy controls and 
correlate with PD-1.3A. 
Results 
PD-1 expression on PBMCs 
At t0 and on unstimulated PBMCs PD-1 receptor expression was low, but 
was significantly increased following activation with αCD3 and αCD28. 
PD-1 expression was significantly lower in the SLE patients and marginally 
lower in the relatives compared to controls. 
PD-1 expression was increased 2.1-fold in the SLE patients, 3.1-fold in 
the relatives and 5.7-fold in the controls. The frequency of PD-1 expressing 
cells and PD-1 expression levels were significantly lower in the SLE patients 
compared to controls. The relatives, however, showed normal numbers of 
PD-1 expressing cells, but significantly lower PD-1 expression levels 
compared to controls.  
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PD-1 expression on CD4+ and CD8+ T cells 
PD-1 expression was induced on both CD4+ and CD8+ T cells after 
stimulation and was significantly lower on CD8+ T cells compared to CD4+ 
T cells in the SLE patients and controls. 
PD-1 expression on CD4+ was significantly lower in both the SLE 
patients and relatives compared to controls, but not significantly different in 
the SLE patients and relatives. 
PD-1 mean MFI on CD8+ cells was significantly lower in the SLE 
patients compared to the relatives and was non-significantly lower in the 
relatives compared to controls.  
PD-1 expression on CD4+CD25+ T cells 
CD4+CD25+ T cells expressed high levels of PD-1, while CD4+CD25- T 
cells did not and there was an increasing gradient of PD-1 expression 
directly correlated to increased CD25 expression. 
PD-1 expression on CD4+CD25+ T cells was significantly lower in both 
the SLE patients and the relatives compared to controls. 
PD-1 was expressed on both FoxP3+ and FoxP3- cells and significant 
differences were not seen in the SLE patient, relatives and controls.  
Correlation of PD-1 expression to PD-1.3A 
For genotype correlation of PD-1 receptor expression, the SLE patients and 
relatives were pooled and A/G SLE and relatives, G/G SLE and relatives and 
G/G controls were compared. 
Lower PD-1 expression levels were seen in A/G SLE and relatives 
compared to G/G SLE and relatives. 
PD-1 MFI on CD4+ and CD8+ T cells was markedly lower in A/G SLE 
and relatives compared to SLE patients G/G SLE and relatives, who in turn 
showed lower PD-1 MFI than G/G controls. 
On CD4 + CD25+ T cells, significantly lower PD-1 expression was 
correlated with the PD-1.3A/G genotype. PD-1 MFI on CD4+CD25+ T cells 
from A/G SLE and relatives was significantly lower compared to G/G SLE 
and relatives and G/G controls. 
A significant difference in PD-1 expression levels was not seen between 
G/G SLE and relatives and G/G controls. 
Discussion 
Analysis of PBMCs revealed significantly lower PD-1 expression in SLE 
patients and relatives, indicating a general effect on different cell 
populations, possibly CD4+ and CD8+ T cells, B cells and monocytes. The 
study, however, focused on CD4+ T cells, but inappropriate activation or 
non-inhibition of autoreactive T cells may lead to loss of self-tolerance. 
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Higher PD-1 levels were correlated with increased expression of CD25 on 
CD4+ T cells, with significantly higher PD-1 MFI levels on CD4+CD25 high 
T cells. PD-1 expression was significantly lower in the SLE patients and the 
relatives compared to controls regardless of CD25 expression levels. 
The frequency of PD-1 expressing cells and PD-1 expression levels were 
significantly lower in the SLE patients compared to controls, while the 
relatives showed normal numbers of PD-1 expressing cells, but significantly 
lower PD-1 expression levels compared to controls. Although there is 
heterogeneity in cell surface receptor expression, the observed differences in 
distribution between SLE patients and relatives compared to controls were 
statistically significant and quite clear with regards to PD-1 expression.  
High PD-1 expression levels on CD4+CD25high cells are consistent with 
prior studies of PD-1 expression on T-regs (331, 332). Therefore, we 
addressed the question of whether the CD4+CD25+ T cells expressing PD-1 
are effector T cells or T-regs or both. T-regs may be distinguished as 
CD4+CD25high cells and some studies use only this marker to identify them. 
Expression of the intracellular FoxP3 transcription factor is, however, a 
more reliable marker for T-regs. We studied PD-1 expression and FoxP3 
expression on CD4+CD25+ cells and found that both FoxP3- T effector cells 
and FoxP3+ T-regs express PD-1. 
CD4+CD25+ T cells expressed high levels of PD-1, while CD4+CD25- T 
cells did not. PD-1 expression on CD4+CD25+ T cells was significantly 
lower in both SLE patients and relatives compared to controls. This 
observation could not be explained by lower numbers of CD4+CD25+ T 
cells and strengthened our belief that PD-1 expression was irregular in SLE 
patients and relatives, and possibly associated with the PD-1.3A allele. 
The final part of the study was a genotype-correlated analysis of PD-1 
expression. Here we were faced with a problem, a lack of individuals 
homozygous for PD-1.3A and a lack of PD-1.3A/G controls. This fact is, 
however, also an interesting point and displays the significant difference in 
PD-1.3 A and G allele distribution in SLE patients and relatives compared to 
non-related healthy controls. 
Our data shows that lower PD-1 expression is correlated to PD-1.3A, 
indicated in lower PD-1 expression levels in A/G SLE and relatives 
compared to G/G SLE and relatives and a non-significant difference between 
G/G SLE and relatives and G/G controls.  
The data points to PD-1.3A having an affect on cellular expression of the 
PD-1 receptor and that PD-1.3A may contribute to loss of self-tolerance and in 
unison with other genetic and/or environmental factors lead to autoimmunity. 
In theory, both SLE patients and relatives having the PD-1.3A/G genotype 
may be genetically programmed for low PD-1 expression, but in the absence 
of other genetic or environmental factors, autoimmunity will not ensue. In 
individuals with SLE or other autoimmune disease, however, other genetic 
factors may be present leading to defects in other immunological pathways. 
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-	Association of three systemic lupus 
erythematosus susceptibility factors, PD-1.3A, C4AQ0, 
and low levels of mannan-binding lectin, with 
autoimmune manifestations in Icelandic multicase 
systemic lupus erythematosus families. 
Background and aims 
The focus of genetic studies of complex diseases, such as autoimmune 
diseases, has been on identifying single susceptibility factors in relation to a 
specific disease or disease phenotype. Susceptibility genes and loci have 
been identified, many of which show ethnic and/or population variability. 
There is increasing evidence for the clustering of multiple autoimmune 
diseases in families and for the overlapping of disease susceptibility loci 
between different autoimmune diseases (16, 78, 333-336). This may be taken 
to suggest common genetic factors for autoimmune diseases (18) where an 
assortment of susceptibility genes, which overlap in different autoimmune 
diseases, may lead to different disease phenotypes depending on the genetic 
composition. 
In our studies on Icelandic multicase SLE families we have identified a 
heterogenetic susceptibility background composed of three susceptibility 
factors; PD-1.3A (69, 81), C4AQ0 (4, 254) and low MBL (171). 
Additionally, there have been indications of increased frequency of 
autoimmune diseases in relatives of the SLE patients in these families.  
This study was undertaken to study further autoimmune diseases other 
than SLE in these families and analyze the relationship of the three 
susceptibility factors and their possible interplay in susceptibility to 
autoimmune diseases. 
The strength of the studies lies in extended, well-defined multicase SLE 
families and a high participation rate, enabling a detailed study on 
autoimmune diseases and autoantibody profiles in the multicase SLE 
families and their association with PD-1.3A, C4AQ0 and low MBL. 
Results 
Autoimmune diseases in the multicase SLE families 
A high frequency of autoimmune diseases other than SLE was seen in the 
families. Of all 124 family members, 18.5% had SLE. Autoimmune diseases 
other than SLE were found in 13.7% of all family members or 16.8% of the 
relatives. Thus, in total, 32.2% of all family members had SLE or other 
autoimmune diseases. 
 50 
The frequency of SLE and autoimmune diseases in the families ranged 
from 14.3% to 30% for SLE and from 14.3% to 50% for the other 
autoimmune diseases. 
Various other autoimmune diseases, one or more, were found in 16.8% of 
the relatives and in 13,7% of the SLE patients themselves. 
ANA and/or other autoantibodies were found in 53.2% of all family 
members, 42.6% of the relatives, and 100% of the patients with SLE. In 
total, 59.7% of family members had SLE, other autoimmune diseases, ANA, 
and/or other autoantibodies. 
Frequency of PD-1.3A, C4AQ0 and low MBL in the families 
The families show heterogeneity for the frequency of PD-1.3A, C4AQ0 and 
low MBL, which ranged from 0-85% in the families. 
C4AQ0 was found in all eight families, in a frequency of 13-85% and was 
significantly increased in five of the families compared to a frequency of 
25% in controls. 
PD-1.3A was found in 6 of the families, in a frequency of 25-70% and 
was significantly increased in five of them compared to a frequency of 10% 
in controls. 
Low MBL was found in seven of the families, in a frequency of 16-60% 
and was marginally increased in frequency in two of the families compared 
to a frequency of 33% in controls. 
All three susceptibility factors were found in five of the families and the 
other three families had two factors present. 
Frequency of PD-1.3A, C4AQ0 and low MBL in the SLE patients and 
the relatives 
The frequency of both PD-1.3A and C4AQ0 was significantly increased in 
the SLE patients, the autoimmune- and non-autoimmune relatives compared 
to controls. The frequency of low MBL was not different in the SLE 
patients, the autoimmune- or non-autoimmune relatives compared to 
controls, in all the eight families pooled. 
However, analysis of “low MBL families” showed a significantly higher 
frequency of low MBL in the SLE patients compared to the autoimmune- 
and non-autoimmune relatives and controls. The most significant difference 
was seen between the SLE patients and the autoimmune relatives, but the 
frequency of low MBL was decreased in the autoimmune relatives. 
Additive effects of the susceptibility factors were analyzed. After 
subdivision of the relatives into autoimmune and non-autoimmune, the 
groups were too small for analyzing potential additive effects of 
combinations of the three susceptibility factors. We did, however, find that 
91% of the SLE patients, 78% of the autoimmune and 75% of the non-
autoimmune relatives carry at least one of the factors. 
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Association of PD-1.3A, C4AQ0 and low MBL with autoantibodies 
Association of PD-1.3A, C4AQ0 and low MBL with autoantibody profiles 
was analyzed by comparison of family members having autoantibodies, 
either only ANA or ANA and other autoantibodies, to family members with 
no autoantibodies. No significant difference was found between the groups. 
Discussion 
Familial clustering of SLE is well documented (4-6) and there are also 
reports of familial aggregation for other autoimmune diseases, such as RA 
(7, 337), SSc (338) psoriatic arthritis (339) and MS (340).  
There is, furthermore, evidence for familial clustering of different 
autoimmune diseases and there are a number of reports of coexistence of 
several autoimmune diseases within the same individual (10). Familial 
clustering of autoimmune diseases in SLE families has mainly been studied 
in single case cohorts, for instance, the study on the GLADEL cohort, which 
demonstrated convincingly familial aggregation of SLE, RA and other 
autoimmune diseases (11). 
The present study, is to our knowledge, the first on autoimmune diseases 
in multicase SLE families. Autoimmune diseases and autoantibodies were 
searched for in a systematic way and a high frequency of autoimmune 
diseases and autoantibodies was found both in the relatives as well as in the 
SLE patients themselves. Compared to an estimated population frequency of 
3-8% (1, 2), there was a significantly increased incidence of autoimmune 
diseases in the families, providing further evidence for familial clustering of 
multiple autoimmune diseases.  
The three susceptibility factors, PD-1.3A, C4AQ0 and low MBL, function 
within immune pathways and are independently associated with SLE in the 
families. C4AQ0 is a unifying susceptibility factor for SLE in all the 
families. PD-1.3A is found in 6 of the 8 families. Low MBL is a minor risk 
factor for SLE, but shows strong association with SLE in those families 
carrying the defect. 
Both C4AQ0 and PD-1.3A are overall increased in frequency in the 
families, both in the group of SLE patients and relatives and may be part of a 
primary genetic susceptibility background for autoimmunity. C4AQ0 is a 
strong risk factor for SLE, while PD-1.3A has shown broader association 
with autoimmunity and has been associated with SLE (91, 93, 299), RA (84, 
87, 92), type 1 diabetes (89, 90), MS (85), AS (86) and Graves´ disease (83, 
88). 
This collective analysis of the multicase SLE families shows that they are 
characterized by a high frequency of autoimmune diseases and 
autoantibodies and by a strong combined genetic susceptibility background.  
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General discussion 
Most human diseases are now recognized to be genetically complex, that is 
there are at least several disease predisposing genetic loci, as well as an 
important role for non-genetic factors (61). 
Susceptibility genes are believed to act either in an additive fashion or by 
way of complex interactions, until a clinical expression threshold is reached. 
The genetic polymorphisms found to be associated with autoimmune 
diseases are usually relatively common and may not affect disease 
susceptibility as long as the combination with other genes and/or 
environmental factors does not pose a risk (16). 
The major genetic factors that have been associated with SLE may be 
broadly classified, with considerable overlap, based on their function into 
genes affecting particular arms of the immune response. 1) Genes affecting 
the innate immune response, such as the genes for complement components 
and FcγR, 2) genes affecting apoptotis, such as genes for Fas and Bcl-2 and 
3) genes affecting the adaptive immune response, such as MHC class II 
genes, cytokine genes and genes for co-inhibitory receptors, for example 
PD-1. 
The impact of environmental factors in disease development is still 
unclear, although several hormonal, occupational and life-style factors have 
been proposed. The fast evolving life-style of humans over the past decades 
may provide new environmental triggers that unleash the effect of “silent” 
susceptibility genes. 
Complement deficiency in SLE 
Complement may be friend or foe, depending on the circumstances. Under 
physiologic conditions, complement promotes the clearance of ICs. If, 
however, ICs are not eliminated, then complement becomes chronically 
activated and can mediate inflammation at sites of IC fallout causing tissue 
injury (341).  
The importance of an intact complement system in the handling of 
circulating ICs has previously been demonstrated in an Icelandic SLE patient 
with complete C2 deficiency (C2Q0) and has directly implicated C2 
deficiency in disease pathogenesis. Infusion of plasma containing C2 
restored binding of IC to CR1 on red blood cells and transport to the 
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reticuloendothelial system (237). It may be speculated that complete C4 
deficiency could predispose to SLE in a similar manner. Complete 
deficiency is, however rare, but partial deficiency or C4AQ0 is common and 
associated with SLE (6, 254-256).  
C4AQ0 is significantly increased in frequency in SLE patients and their 
relatives from Icelandic multicase families. The genetic basis of C4AQ0 
varies and C4AQ0 is found on different MHC haplotypes (254). A C4A gene 
deletion accounts for 2/3 of C4AQ0 alleles and the deletion is found on 3 
different MHC haplotypes (Paper I). 
This points to C4AQ0 as an independent risk factor in SLE. Providing 
further support is the reported association of C4AQ0 with SLE in different 
populations and ethnic groups and the varying genetic mechanisms and 
MHC haplotypes associated with C4AQ0 in these cohorts. For example, in 
Japanese SLE patients, C4AQ0 is associated with disease, but the genetic 
background of C4AQ0 differs from that seen in Caucasians. In Japanese 
cohorts the C4A gene deletion is not found (342). C4AQ0 may thus 
contribute to the pathogenesis of SLE beyond the ethnical differences.  
Yet another point, supporting C4AQ0 as an independent risk factor is the 
association of other complement deficiency states with SLE, namely 
deficiency of C1 and low MBL, but the structural genes for C1 and MBL are 
not located within the MHC.  
Low MBL genotypes, which are correlated with low serum MBL levels, 
are also found to be associated with SLE in the Icelandic families. Unlike 
C4AQ0, which is found in a high background in most of the families, low 
MBL is restricted to five of the families. In these “low MBL families”, low 
MBL is associated with SLE and presents additive risk in combination with 
C4AQ0 (Paper II). 
Prior studies have suggested that low MBL may be a minor risk factor for 
SLE, but stratifying the families for this particular genetic trait showed a 
significant association with SLE. This may again reflect the effect of genetic 
heterogeneity, not only when studying different populations or ethnic 
groups, but also when studying different families within the same 
population. 
Deficiency of complement components may lead to impaired clearance of 
apoptotic cells and immune complexes and affect maintenance of self-
tolerance. 
Deposition of ICs in peripheral tissues may lead to inflammation and 
tissue damage with increased release of autoantigens initiating a cycle of 
enhanced autoantibody production, decreased clearance and deposition of 
ICs, inflammation and tissue damage (237).  
Deficiency of classical complement components may further affect self-
tolerance through decreased opsonization of target autoantigens with C3d 
and diminished localization of autoantigens in the bone marrow.  
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Impaired complement mediated clearance of apoptotic cells may also lead 
to loss of self-tolerance. Normally in peripheral tissues, apoptotic cells are 
cleared very early by tissue macrophages, which produce anti-inflammatory 
cytokines and downregulate the antigen presentation function of DCs. It has 
also been suggested that immature DCs that have taken up apoptotic cells 
receive signals from the apoptotic cell, possibly via CR3, that inhibit 
development of antigen-presenting function of the DC (239, 240). The DC is 
thus not able to present self-antigens harbored in the apoptotic cell to 
autoreactive T cells and self-tolerance is preserved. 
In complement deficiency states, where apoptotic cells and ICs are not 
cleared there is both an abundant amount of autoantigens for uptake by DCs 
and there is also an ongoing inflammatory response or danger milieu. 
Danger signals, such as pro-inflammatory cytokines, which stimulate DC 
maturation and activate macrophages, induce maturation of immature 
macrophages to DCs capable of antigen presentation to autoreactive T cells 
(232, 241). 
The PD-1 pathway in SLE 
Autoimmune diseases are the result of loss of self-tolerance, which may be a 
consequence of aberrancies in different immune pathways. Among the 
regulators of self-tolerance are T cell co-inhibitory receptors CTLA4 and 
PD-1 (82, 291, 343). 
Polymorphisms in the PDCD1 gene have now been associated with SLE 
and other autoimmune diseases in different populations. The most widely 
studied polymorphism is PD-1.3A. PD-1.3A shows strongest association 
with SLE in Caucasian populations, suggesting that the mutation is recent 
and affects mostly Europeans and has a lesser effect in populations admixed 
with them (81, 307). Interestingly, other PDCD1 gene polymorphisms have 
been associated with SLE in non-Caucasian populations (93, 304, 310). 
There is limited information on cellular expression of the PD-1 receptor 
in humans and our analysis is a step towards clearing that picture. Our data 
show lower expression of the PD-1 receptor in SLE patients and relatives 
correlated with PD-1.3A (Paper III). PD-1 expression on activated 
CD4+CD25+ T cells, both T effector cells and T-regs, was significantly 
lower in the SLE patients and their relatives, compared to controls. 
Aberrant PD-1 expression may affect CD4+CD25+ effector T cell 
function by altering activation thresholds leading to activation of 
autoreactive T cells. The PD-1 pathway has been reported to be important in 
regulating T-regulatory cell functions, but whether the effect is direct is not 
clear (82, 344, 345). Regulatory cell function has been shown to persist in 
the absence of the PD-1/PD-L1 or CTLA4/B7 pathways, but higher ratios of 
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CD4+CD25high T cells have also been shown to be required to suppress 
proliferation if PD-L1 receptor is blocked (346). 
It will be important to study the phenotype of both CD4+CD25+ effector 
and regulatory T cells in relation to disease activity. Moreover, to study 
proliferative responses, cytokine profiles, and interactions with antigen 
presenting cells, autoantibody production and PD-1 expression on B cells. 
Familial clustering of autoimmune diseases 
Paper IV is a compiled analysis of available data on the Icelandic multicase 
SLE families, including PD-1.3A, C4AQ0, low MBL, other autoimmune 
diseases and autoantibody profiles. 
The study demonstrates a high frequency and clustering of different 
autoimmune diseases and autoantibodies in families that are heterogeneous 
regarding the genetic susceptibility factors, PD-1.3A, C4AQ0 and low MBL. 
PD-1.3A and C4AQ0 may be part of a genetic background predisposing 
family members to autoimmune diseases. Such a “predisposing” genetic 
background may partially explain the apparent clustering of different 
autoimmune diseases in the families, but as demonstrated by an increased 
frequency of PD-1.3A and C4AQ0 in the non-autoimmune relatives, other 
genetic and/or environmental factors may be necessary for disease 
expression. Interestingly, other genetic factors have been identified in these 
families; low MBL, increased numbers of IL-10 producing cells (51) and 




Familial aggregation of different autoimmune diseases may have several 
explanations including genetic polymorphisms that impair immune pathways 
that maintain self-tolerance. As maintenance of self-tolerance is dependent 
on complex interactions of many components, different compilations of 
genetic polymorphisms affecting regulation of the immune response at 
different levels, may be responsible for different autoimmune diseases in 
different families. Still other disease specific genetic and/or environmental 
factors may subsequently determine the organ or tissues targeted by the 
autoimmune response, thereby determining the autoimmune phenotype (18).  
Analyzing independent susceptibility factors may be the first step in 
creating a unifying picture of intertwining factors and pathways that can 
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